benserazide has been researched along with Idiopathic Parkinson Disease in 340 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study determined the effects of single doses of opicapone (OPC), a novel third-generation catechol-O-methyltransferase (COMT) inhibitor, on levodopa and 3-O-methyl-levodopa (3-OMD) pharmacokinetics (PK), COMT activity and motor fluctuations in patients with Parkinson disease (PD)." | 9.22 | Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ( Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P, 2016) |
| "The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations." | 9.14 | Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010) |
| "A sixteen-week study examined the effect of Madopa and Sinemet on patients with Parkinson disease disease suffering nausea or vomiting as side-effects of levodopa therapy and compared the efficacy of the three preparations in controlling the symptoms of Parkinson disease." | 9.04 | A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease. ( Diamond, SG; Markham, CH; Treciokas, LJ, 1978) |
| "Plasma levodopa and therapeutic responses to treatment with levodopa in combination with benserazide or carbidopa were studied in 49 patients with Parkinson disease not previously treated with levodopa in a blind randomized crossover trial." | 9.04 | Levodopa with benserazide or carbidopa in Parkinson disease. ( Mölsä, P; Rinne, UK, 1979) |
| "A retrospective cohort study of 21 patients on levodopa/benserazide and one patient on levodopa-carbidopa intestinal gel with clinically suspected or biopsy proven microscopic colitis." | 8.02 | Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction. ( Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ, 2021) |
| "This study aims to investigate hyperhomocysteinemia (HHcy) resulted from treatment in patients with Parkinson's disease (PD) and to evaluate the therapeutic outcome of HHcy." | 7.83 | The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. ( Cao, LD; Guo, G; Wu, QY; Xu, S, 2016) |
| "For many patients with Parkinson disease and levodopa-related motor fluctuations, the latency to onset of action of a single dose of a levodopa preparation may be both long and variable." | 7.68 | The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. ( Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F, 1992) |
| " The main levodopa pharmacodynamic variables were the maximum percentage increase in tapping frequency over baseline values (ΔTapmax %) and the area under the tapping effect-time curve (AUCTap)." | 5.43 | Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease. ( Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Doria, A; Guaraldi, P; Lopane, G; Martinelli, P, 2016) |
| "Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease." | 5.38 | Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease. ( Munhoz, RP; Teive, HA; Zavala, JA, 2012) |
| " Two dosage strengths are available: 100 mg levodopa plus 25 mg benserazide and 50 mg levodopa plus 12." | 5.29 | [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease]. ( Dessibourg, CA; Gachoud, JP, 1995) |
| " Due to a lower bioavailability of the slow release formulation--the latter is based on the "hydrodynamically balanced system" (HBS)--, the patients remained initially on their time schedule of drug intake but received a higher dose of L-DOPA slow release compared to the preceding L-DOPA standard therapy." | 5.29 | [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. ( Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C, 1995) |
| "This study determined the effects of single doses of opicapone (OPC), a novel third-generation catechol-O-methyltransferase (COMT) inhibitor, on levodopa and 3-O-methyl-levodopa (3-OMD) pharmacokinetics (PK), COMT activity and motor fluctuations in patients with Parkinson disease (PD)." | 5.22 | Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease. ( Almeida, L; Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P, 2016) |
| "The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations." | 5.14 | Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. ( Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010) |
| "A sixteen-week study examined the effect of Madopa and Sinemet on patients with Parkinson disease disease suffering nausea or vomiting as side-effects of levodopa therapy and compared the efficacy of the three preparations in controlling the symptoms of Parkinson disease." | 5.04 | A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease. ( Diamond, SG; Markham, CH; Treciokas, LJ, 1978) |
| "Plasma levodopa and therapeutic responses to treatment with levodopa in combination with benserazide or carbidopa were studied in 49 patients with Parkinson disease not previously treated with levodopa in a blind randomized crossover trial." | 5.04 | Levodopa with benserazide or carbidopa in Parkinson disease. ( Mölsä, P; Rinne, UK, 1979) |
| "A retrospective cohort study of 21 patients on levodopa/benserazide and one patient on levodopa-carbidopa intestinal gel with clinically suspected or biopsy proven microscopic colitis." | 4.02 | Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction. ( Babu, S; Chang, FC; Dal, S; Fletcher, N; Fung, VSC; Mahant, N; Martin, AJ; Morales-Briceno, H; Nankervis, J; Ong, TL; Robbie, M; Williams, LJ, 2021) |
| "This study aims to investigate hyperhomocysteinemia (HHcy) resulted from treatment in patients with Parkinson's disease (PD) and to evaluate the therapeutic outcome of HHcy." | 3.83 | The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. ( Cao, LD; Guo, G; Wu, QY; Xu, S, 2016) |
| " The present results show beneficial antioxidant and methyl donor properties of betaine versus oxidative stress and hyperhomocysteinemia induced by levodopa and benserazide in an animal model." | 3.81 | Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats. ( Alirezaei, M; Dezfoulian, O; Khoshdel, Z; Rashidipour, M; Taghadosi, V, 2015) |
| " The aims of this study were therefore (1) to investigate the anti-dyskinetic effects of piribedil on L-DOPA-induced contralateral turning behaviour, locomotive dyskinesias (LD), axial dystonia (AD), orolingual dyskinesia (OD) and forelimb dyskinesia (FD) and (2) to compare these effects to the α(2) adrenoceptor antagonist, idazoxan, or the α(2) adrenoceptor agonist, clonidine." | 3.79 | The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. ( Gerlach, M; Halley, P; Riederer, P; van den Buuse, M, 2013) |
| "For many patients with Parkinson disease and levodopa-related motor fluctuations, the latency to onset of action of a single dose of a levodopa preparation may be both long and variable." | 3.68 | The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. ( Bramante, L; Quinn, NP; Ruggieri, S; Steiger, MJ; Stocchi, F, 1992) |
| "Parkinsonian patients with orthostatic hypotension and dizziness due to usual antiparkinson therapy have been treated with the precursor amino-acid of noradrenaline, DL-3,4-threo-dihydroxyphenylserine (DL-3,4-threo-DOPS)." | 3.66 | DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness. ( Birkmayer, G; Birkmayer, W; Lechner, H; Riederer, P, 1983) |
| "The changes in prolactin release induced by acute doses of L-Dopa + benserazide (250 mg) were analysed in Parkinson disease patients undergoing various drug treatments." | 3.66 | [Exploration of the tubero-hypophyseal dopaminergic system in patients with chronic parkinsonism during chronic treatment with L-DOPA]. ( Baldassarre, G; Fazio, B, 1983) |
| "In four patients with Parkinson disease, we compared carbidopa combined with levodopa (Sinemet) and benserazide combined with levodopa (Madopar)." | 3.66 | Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease. ( Estey, E; Goldstein, M; Gopinathan, G; Lieberman, A; Ohashi, T; Sauter, A, 1978) |
| "The relationship between dopamine receptor stimulation by bromocriptine or levodopa and the relief of parkinsonism was studied in 24 patients with Parkinson disease." | 3.66 | Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa. ( Marttila, R; Rinne, UK, 1978) |
| "While several generic preparations of levodopa/carbidopa and levodopa/benserazide (LBD) are currently available, pharmacokinetic (PK) equivalence and therapeutic equivalence studies with levodopa generics are not available in Italy." | 2.90 | Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar). ( Alessandroni, J; Bonassi, S; Bravi, D; Casali, M; Fossati, C; Grassini, P; Ialongo, C; Onofrj, M; Radicati, FG; Stocchi, F; Torti, M; Vacca, L, 2019) |
| "Micrographia is a common symptom in Parkinson's disease, which manifests as either a consistent or progressive reduction in the size of handwriting or both." | 2.82 | Neural correlates underlying micrographia in Parkinson's disease. ( Chan, P; Feng, T; Hallett, M; Hou, Y; Wu, T; Zhang, J, 2016) |
| "Two levodopa tests were performed, one at baseline and another following the maintenance phase." | 2.80 | Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. ( Falcão, A; Ferreira, JJ; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P, 2015) |
| " Reported adverse events were comparable between LB and LC users." | 2.80 | Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. ( Kuoppamäki, M; Leinonen, M; Poewe, W, 2015) |
| " Adverse effects from Western drug-based medical intervention prevent long-term adherence to these therapies in many patients." | 2.78 | Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial. ( Ma, YZ; Shen, XM; Zhang, J, 2013) |
| "Oral levodopa dosing was increased in 28% of patients; the primary outcome remained significant when these patients were excluded." | 2.75 | Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. ( Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O, 2010) |
| "Other efficacy variables (Unified Parkinson's Disease Rating Scale II, III, and IVb and Investigator's Global Assessment scores) improved significantly after switching to tolcapone." | 2.75 | Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. ( Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R, 2010) |
| "Treatment with levodopa/carbidopa/entacapone resulted in significantly greater improvements in PDQ-8 scores compared to treatment with levodopa/carbidopa (mean difference 1." | 2.74 | Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. ( Fung, VS; Herawati, L; Wan, Y, 2009) |
| "Fifty cases in a treatment group were treated by acupuncture combined with madopar, and 30 cases in a control group treated by madopar only." | 2.73 | Fifty cases of Parkinson's disease treated by acupuncture combined with madopar. ( Ren, XM, 2008) |
| " Long-term levodopa administration results in an increased levodopa plasma bioavailability in PD patients." | 2.71 | Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. ( Muhlack, S; Müller, T; Przuntek, H; Twiehaus, S; Welnic, J; Woitalla, D, 2004) |
| " The main levodopa pharmacokinetic outcome variables were time to peak and peak plasma concentration, plasma elimination half-life, and the area under the plasma concentration-time curve." | 2.71 | Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. ( Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Mochi, M; Riva, R, 2005) |
| " Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half life, thereby prolonging the efficacy of levodopa." | 2.69 | Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. ( Baas, H; Beiske, AG; Ghika, J; Jackson, M; Oertel, WH; Poewe, W; Ransmayr, G, 1998) |
| "When tolcapone was combined with 25 mg benserazide the elevation was small." | 2.69 | The effect of tolcapone on the pharmacokinetics of benserazide. ( Beiske, A; Fotteler, B; Jorga, KM; Larsen, JP; Moe, B; Schleimer, M; Schmitt, M, 1999) |
| " Tolcapone increased the bioavailability (AUC 0-infinity) and apparent elimination half-life (t(1/2)) of levodopa by 80 and 40%, respectively, compared to placebo." | 2.69 | COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease. ( Crevoisier, C; Gasser, UE; Hovens, SE; Jorga, K; van Giersbergen, PL, 1999) |
| "The pharmacokinetic model which best described the data was a two-compartment open model with first-order absorption and possibly a lag-time." | 2.69 | Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. ( Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL, 2000) |
| "Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2)." | 2.68 | Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. ( Lees, AJ, 1995) |
| "Tremor was assessed via accelerometry and surface EMG." | 2.68 | 'Atypical' tremor. ( Byth, K; Einstein, R; Henderson, JM; Jackson, DM; Morris, JG, 1995) |
| " The drugs were dosed according to the individual need of the patients." | 2.68 | Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. ( Andersen, A; Boas, J; Boisen, E; Borgmann, R; Buch, D; Dupont, E; Helgetveit, AC; Kjaer, MO; Kristensen, TN; Mikkelsen, B; Pakkenberg, H; Presthus, J; Stien, R; Worm-Petersen, J, 1996) |
| "5%, probably reflecting some differences in the bioavailability of the various galenical formulations, and the mean daily drug intakes were reduced from 5." | 2.68 | Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group. ( Gachoud, JP; Gasser, U; Ghika, J, 1997) |
| "Ten patients with a diagnosis of idiopathic Parkinson's disease and motor fluctuations otherwise unresponsive to conventional therapy were selected." | 2.67 | [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa]. ( Casas Parera, I; Diaz, S; Fernández Pardal, MM; Gatto, E; Micheli, F, 1991) |
| " The present study, therefore, compared single dose kinetics and pharmacodynamic effects of three dosages of L-dopa/bensearazid-s." | 2.67 | [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness]. ( Baas, H; Bergemann, N; Fischer, PA, 1994) |
| "Patients with Parkinson's disease (PD) are more dependent on visual information during movements than normals." | 2.67 | Visual control of arm movement in Parkinson's disease. ( Dichgans, J; Klockgether, T, 1994) |
| "In the Parkinson's disease group studied, the frequency, EMG pattern of bursts, and response to L-Dopa were similar for the two tremors (median improvement of RT by 70% and PT by 61%)." | 2.67 | Postural tremor of Parkinson's disease. ( Byth, K; Einstein, R; Henderson, JM; Jackson, D; Morris, JG; Yiannikas, C, 1994) |
| " The results of the substitution phase show that combined treatment permitted a mean reduction of the levodopa dosage by 40%, without deterioration of therapeutic response." | 2.67 | Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report. ( Kraus, PH; Letzel, H; Przuntek, H; Schwarzmann, D; Welzel, D, 1992) |
| "20 patients with Parkinson's disease and a fluctuating response to chronic treatment with conventional L-dopa preparations participated in an open randomized trial comparing two sustained-release L-dopa preparations (Madopar HBS, Sinemet CR4)." | 2.67 | Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. ( Kleedorfer, B; Poewe, W, 1992) |
| "Temazepam was consistently less potent than chlormethiazole on tests of drowsiness and psychomotor performance." | 2.67 | A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients. ( Ashwood, TJ; Bateman, DN; Tulloch, JA; Woodhouse, KW, 1991) |
| " The equivalent L-dopa dosage had to be increased by 56% (29-100%) with Madopar HBS while mean dopamine levels increased in four patients (by 47-257%) without the occurrence of peripheral side-effects." | 2.67 | Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients. ( Ceballos-Baumann, AO; Eckert, W; von Kummer, R; Weicker, H, 1990) |
| " The mean optimum total daily dosage of conventional Madopar was 820 mg taken in a mean of 6." | 2.67 | A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. ( Blackburn, NA; Boddie, HG; Ellis, CJ; Kendal, BR; MacMahon, DG; Sachdev, D, 1990) |
| " In 13 patients a considerable diminution in nocturnal akinesia and in the frequency of waking up was reached with a mean dosage of 308 mg of Madopar HBS." | 2.67 | Madopar HBS in nocturnal symptoms of Parkinson's disease. ( Jansen, EN; Meerwaldtt, JD, 1990) |
| " The results suggest, the BH4 in the dosage used, is not effective in the treatment of Parkinson's disease." | 2.66 | Tetrahydrobiopterin and Parkinson's disease. ( Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V, 1989) |
| " Even better results could be accomplished in an extended trial attempting to establish the best dosage ratio of the combination, possibly admitting increased dosage." | 2.66 | A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease. ( Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A, 1988) |
| "Of the three main symptoms of Parkinson's disease, the best effect was seen on tremor, and less pronounced effects on bradykinesia and rigidity." | 2.66 | Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo. ( Bliesath, H; Jellinger, K, 1987) |
| " During the first month the dosage titration was aimed at finding the optimal therapeutic effect." | 2.66 | Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy. ( Aymard, N; Holzer, J; Rondot, P; Ziegler, M, 1987) |
| "In a open study in 13 patients with Parkinson's disease with 'on-off' fluctuations, all (n = 3) or part (n = 10) of the usual intake of levodopa (with peripheral decarboxylase inhibitor) was replaced by Madopar HBS for 5-122 days (median 35)." | 2.66 | Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations. ( Marion, MH; Marsden, CD; Quinn, NP, 1987) |
| " The clinical response to Madopar HBS was delayed and brief; the relative bioavailability was only 50%." | 2.66 | Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. ( Jenner, P; Malcolm, SL; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F, 1987) |
| " At the beginning the patients were switched from standard Madopar to Madopar HBS, initially keeping constant L-dopa dosage and the number of daily doses." | 2.66 | Open clinical study of Madopar HBS. ( Ludin, HP, 1987) |
| " However, with the new formulation the dosage had to be increased by 86% on average as compared with standard Madopar." | 2.66 | Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study. ( D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP, 1987) |
| " For the first few days (up to 1 week) dosage and number of daily intakes of HBS were the same as those of the standard formulation." | 2.66 | Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations. ( Baas, H; Fischer, PA, 1987) |
| " The overall increase in dosage of levodopa with Madopar HBS was 54% in comparison with the initial standard Madopar dosage." | 2.66 | Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment. ( Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J, 1987) |
| "In 3 patients with longstanding Parkinson's disease treated with Madopar or Nacom, who were not included in the study, the doses of the above drugs could be maintained or reduced by addition of deprenyl." | 2.66 | Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial. ( Grundmann, M; Schimrigk, K, 1987) |
| " The frequency of drug intake was unaltered but daily dosage could be increased by 30% without increasing severity of abnormal movements to a similar degree." | 2.66 | [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease]. ( Aymard, N; Holzer, J; Rondot, P; Ziegler, M, 1987) |
| " The dosage of drug was titrated at each visit to give minimum risk with acceptable benefit." | 2.66 | Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. ( Admani, AK; Cordingley, GJ; Harris, RI; Verma, S, 1985) |
| " Subsequently they were treated with either a mean dosage of 444 mg levodopa and benserazide (47 patients) or a combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine (32 patients)." | 2.65 | [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study]. ( Fischer, PA; Majer, M; Przuntek, H; Welzel, D, 1984) |
| " Mean daily maintenance dosage was 612." | 2.65 | Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism. ( Carlyle, D; Williams, BO, 1979) |
| " With both drugs, Madopar or Sinemet, an optimum therapeutic result was obtained with relatively small doses of L-dopa (the reduction in L-dopa dosage amounting to about 80%)." | 2.65 | [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. ( Birkmayer, W; Mentasti, M; Podiwinsky, F; Riederer, P, 1979) |
| " Patients were allocated at random to treatment with either levodopa + benserazide ratio 4:1 (Madopar) or levodopa + carbidopa ratio 10:1 (Sinemet) using dosage schedules recommended by the manufacturers which they had to adhere to for 6 months." | 2.64 | Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial. ( Birket-Smith, E; Dupont, E; Hansen, E; Mikkelsen, B; Pakkenberg, H; Presthus, J; Rautakorpi, I; Riman, E; Rinne, UK, 1976) |
| "The treatment of patients suffering from idiopathic Parkinson's disease has become more and more complex." | 2.43 | [Idiopathic Parkinson's disease: practical hints for the treatment]. ( Ludin, HP, 2005) |
| "Amantadine has been teratogenic in rats and selegiline has caused neurochemical and behavioral alterations in rats when coadministered with clorgyline." | 2.40 | Pregnancy in Parkinson's disease: a review of the literature and a case report. ( Hagell, P; Odin, P; Vinge, E, 1998) |
| " Administration in daily dosage of 10 mgs produces an almost complete inhibition of the enzyme." | 2.37 | R-(-)-deprenyl and parkinsonism. ( Yahr, MD, 1987) |
| "Levodopa has been shown to be a safe pharmacologic agent even after long-term usage." | 2.35 | Levodopa. ( Yahr, MD, 1975) |
| " The subjects in the control group received only levodopa and benserazide hydrochloride treatment, while the observation group was treated with Resagiline in combination with the clinical control group." | 1.91 | Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease. ( Gao, F; Gao, L; Miao, J; Yang, Y, 2023) |
| " The relationship between the difference in the DCI to levodopa ratio and the development of motor complications in long-term administration of levodopa is unknown." | 1.72 | The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study. ( Baba, Y; Futamura, A; Kinno, R; Nabeshima, Y; Nomoto, S; Osakabe, Y; Shoji, D; Takahashi, S; Yasumoto, T, 2022) |
| "Benserazide is used in the treatment of Parkinson's disease and was noticed to induce gamma globin in preclinical models." | 1.62 | Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders. ( Costa, FF; de Azevedo, PC; Fertrin, KY; Leonardo, DP; Olops, L; Piovesana, LG; Santos, MEHP; Tavares, AHJ; Vendrame, F, 2021) |
| "Parkinson's disease is clinically defined by bradykinesia, along with rigidity and tremor." | 1.56 | Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype. ( Cools, R; den Ouden, HEM; Dirkx, MF; Helmich, RC; Toni, I; van Nuland, AJ; Zach, H, 2020) |
| "Benserazide is an irreversible inhibitor of peripheral aromatic L-amino acid decarboxylase that prevents the breakdown of levodopa in the bloodstream." | 1.48 | Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis. ( Etminan, N; Rahmanifar, E; Yoosefian, M, 2018) |
| "Re-emergent tremor is a continuation of resting tremor during stable posturing, and it has a dopaminergic basis." | 1.48 | The nature of postural tremor in Parkinson disease. ( Bloem, BR; Dirkx, MF; Hallett, M; Helmich, RC; Zach, H, 2018) |
| "The aim of our study was to assess the frailty phenotype prevalence in geriatric inpatients with mild parkinsonian signs (MPS) and to investigate levodopa test in the frail patients with MPS." | 1.46 | Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs. ( Bugdol, M; Czernek, M; Derejczyk, J; Kapko, W; Kawa, J; Marcisz, C; Seiffert, P; Stępień-Wyrobiec, O; Szymszal, J; Torbus, A, 2017) |
| "In this case report, we describe a Parkinson's disease (PD) patient with limb-kinetic apraxia (LKA) in whom degeneration of the corticofugal tract (CFT) from the supplementary motor area (SMA) was observed in diffusion tensor tractography (DTT)." | 1.46 | Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report. ( Chang, MC; Lee, HD, 2017) |
| " The main levodopa pharmacodynamic variables were the maximum percentage increase in tapping frequency over baseline values (ΔTapmax %) and the area under the tapping effect-time curve (AUCTap)." | 1.43 | Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease. ( Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Doria, A; Guaraldi, P; Lopane, G; Martinelli, P, 2016) |
| "Parkinson's disease is a neurodegenerative disorder characterized by a loss of nigrostriata dopaminergic neurons, which has been thought, at least in part, to result from oxidative stress." | 1.43 | Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system. ( Du, N; Guo, Z; Han, M; Huang, Y; Liu, J; Xu, S, 2016) |
| "Levodopa (l-DOPA) has been proved to reverse the pathologic neuron activities in many brain regions related to Parkinson's disease (PD)." | 1.43 | Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease. ( Geng, X; Han, H; Hou, Y; Lei, C; Li, M; Wang, M; Wang, X; Xie, J; Yao, X; Zhang, Q; Zhang, X, 2016) |
| " Rats were dosed orally with Tozadenant, a selective A2A receptor antagonist, and three different doses of Radiprodil, an NR2B-selective NMDA receptor antagonist." | 1.42 | Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs. ( De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X, 2015) |
| "Although patients with Parkinson's disease show impairments in cognitive performance even at the early stage of the disease, the synaptic mechanisms underlying cognitive impairment in this pathology are unknown." | 1.38 | Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. ( Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A, 2012) |
| "Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease." | 1.38 | Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease. ( Munhoz, RP; Teive, HA; Zavala, JA, 2012) |
| "Psychotic features in patients with Parkinson's Disease usually present as visual hallucinations against a background of cognitive deterioration and dopaminomimetic therapy." | 1.36 | Isolated delusional syndrome in Parkinson's Disease. ( Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N, 2010) |
| " Based on the results of rotational behavior and forelimb hyperkinesia in Week 5, the rats were allocated to three treatment groups (saline and two dosing rates of piclozotan set at 0." | 1.36 | Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. ( Inoue, T; Koyama, M; Ogata, A; Tani, Y, 2010) |
| "We studied 10 Parkinson's disease patients and examined adipose tissue and skeletal muscle metabolism directly with microdialysis." | 1.35 | Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease. ( Adams, F; Boschmann, M; Franke, G; Gottschalk, S; Janke, J; Jordan, J; Kupsch, A; Leisse, MC; Lipp, A; Lobsien, E; Spranger, J, 2008) |
| "A marked reversal of dystonia was produced in the first seven patients by the withdrawal or dose decrease of dopaminergic PS priming drug, and in the eighth patient an increase of dopaminergic therapy was necessary." | 1.35 | Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy. ( Cannas, A; Floris, G; Marrosu, F; Marrosu, MG; Piga, M; Serra, A; Solla, P; Tacconi, P, 2009) |
| "Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias." | 1.32 | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. ( Einarson, TR; Iskedjian, M, 2003) |
| "Benserazide is commonly used for Parkinson's disease in combination with L-DOPA as a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor." | 1.32 | Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. ( Arai, A; Kannari, K; Matsunaga, M; Shen, H; Yamato, H, 2003) |
| "Delusional jealousy in Parkinson's disease has rarely been reported in the scientific literature." | 1.31 | [A case of delusional jealousy in Parkinson disease ]. ( Brüne, M; Gerlach, G; Schröder, SG, 2001) |
| "Six patients with Parkinson's disease who had troublesome motor complications under levodopa/DCI and DA agonist combination therapy were compared in terms of the extent of motor complications and their satisfaction after changing their therapy from levodopa/DCI to levodopa without DCI." | 1.31 | [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. ( Hironishi, M; Kondo, T; Miwa, H, 2002) |
| "Dysphagia is a frequent and potentially serious complication of Parkinson's disease (PD)." | 1.30 | Swallowing difficulty in Parkinson's disease. ( Chiang, JH; Fuh, JL; Lee, RC; Lin, CH; Liu, HC; Wang, PN; Wang, SJ, 1997) |
| " Daily levodopa dosage requirements decreased significantly." | 1.30 | Highlights of the North American and European experiences. ( Goetz, CG, 1998) |
| "Four of the patients had similar pharmacokinetic patterns for L-dopa and a significant (P < 0." | 1.30 | L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma. ( Dizdar, N; Granérus, AK; Hannestad, U; Kågedal, B; Kullman, A; Ljungdahl, A; Olsson, JE, 1999) |
| " Two dosage strengths are available: 100 mg levodopa plus 25 mg benserazide and 50 mg levodopa plus 12." | 1.29 | [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease]. ( Dessibourg, CA; Gachoud, JP, 1995) |
| "A 64-year-old man was diagnosed to have Parkinson's disease when aged 42 years and since then has been treated with levodopa and benserazide (up to 875 mg daily)." | 1.29 | [Bromocriptine-induced pleuropneumopathy]. ( Eberli, F; Greminger, P; Schmid, PA; Speich, R; Suter, T, 1994) |
| "Seven patients with idiopathic Parkinson's disease, aged 62 to 76 years, average duration of the disease approximately eleven years, suffering from severe hallucinosis and paranoid delusions of different degree, in whom conventional therapeutic strategies (administration of benzodiazepines and mild neuroleptics) had no antipsychotic effect, received clozapine, a non-classical highly potent neuroleptic, while blood count was strictly monitored." | 1.29 | Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. ( Helscher, RJ; Pinter, MM, 1993) |
| "Levodopa treatment might change the dopaminergic and serotoninergic neuronal systems, but not the noradrenergic or adrenergic neuronal systems, in CNS of PD patients." | 1.29 | Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. ( Cheng, FC; Chia, LG; Kuo, JS, 1993) |
| " Due to a lower bioavailability of the slow release formulation--the latter is based on the "hydrodynamically balanced system" (HBS)--, the patients remained initially on their time schedule of drug intake but received a higher dose of L-DOPA slow release compared to the preceding L-DOPA standard therapy." | 1.29 | [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. ( Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C, 1995) |
| " As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened." | 1.29 | Clinical implications of sustained dopaminergic stimulation. ( Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F, 1994) |
| "In patients with Parkinson's disease the levels of somatostatin-like immunoreactivity were lower than in controls (P less than ." | 1.28 | Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy. ( Cramer, H; Kuntzmann, F; Masson, H; Popescu, I; Strubel, D, 1990) |
| "When benserazide was coadministered with RO 40-7592 (10 mg/kg) a dose-dependent decrease in striatal k3 was measured with an apparent ED50 of 3 mg/kg." | 1.28 | Central action of benserazide after COMT inhibition demonstrated in vivo by PET. ( Andersson, Y; Antoni, G; Bjurling, P; Hartvig, P; Långström, B; Tedroff, J, 1991) |
| "The current study on 36 patients with Parkinson's disease under long-term treatment with levodopa/dopadecarboxylase inhibitor showed, however, that the erythrocyte-COMT was unaffected by additional (-)-deprenyl medication." | 1.28 | (-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity. ( Dettner, O; Gerlach, M; Kuhn, W; Przuntek, H; Russ, H, 1991) |
| " The negative aspects of Madopar HBS are a lower bioavailability that means a dosage increase and a longer latency for the therapeutic response in the morning." | 1.28 | Long-term treatment with Madopar HBS in parkinsonians with fluctuations. ( Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A, 1990) |
| "Fifty four patients with idiopathic Parkinson's disease receiving levodopa therapy were studied." | 1.28 | Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. ( Berger, HJ; Horstink, MW; Pasman, JW; van't Hof, MA; Zijlmans, JC, 1990) |
| "Selegiline was capable of enhancing the antiparkinsonian effect of the new formula of L-DOPA, while allowing a reduction of the doses administered." | 1.28 | Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients. ( Aljanati, R; Buzo, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Romero, S; Scaramelli, A, 1989) |
| " The optimal therapeutic dosage of Sinemet CR was equal to that of Madopar HBS but 12% higher than that of standard Madopar." | 1.28 | Treatment of early Parkinson's disease with controlled-release levodopa preparations. ( Rinne, JO; Rinne, UK, 1989) |
| " The effects of L-Dopa dosage adjustments after hospitalization were particularly considered." | 1.28 | [The problems of L-dopa therapy in the course of Parkinson syndrome]. ( Emskötter, T; Heidenreich, C; Lachenmayer, L, 1989) |
| " Plasma ALAAD 2 hours after dosing was normal in Groups I and II." | 1.28 | Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism. ( Boomsma, F; Hovestadt, A; Man in 't Veld, AJ; Meerwaldt, JD; Schalekamp, MA, 1989) |
| " The model is then used to optimize the dosage regimen for each patient individually (according to the clinical particularities and needs of each patient) with respect to an objective function which includes the symptoms dynamically and the total amount of levodopa which is to be administered." | 1.28 | Optimization of symptomatic therapy in Parkinson's disease. ( Albani, C; Hacisalihzade, SS; Mansour, M, 1989) |
| " Following effective stereotaxic surgery, drug therapy should be continued with reduced dosage of the drugs." | 1.27 | [Combined (surgical and drug) therapy of parkinsonism]. ( Iadgarov, IS; Kandel', EI, 1984) |
| "In the initial stage of Parkinson's disease deprenyl is only partially sufficient as monotherapy." | 1.27 | Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. ( Csanda, E; Tárczy, M, 1983) |
| "A 77-year-old man with Parkinson's disease of long standing, under treatment with L-DOPA and benserazide, was administered DL-threo-3, 4-dihydroxyphenylserine (DL-threo-DOPS), a precursor of norepinephrine, for 10 days." | 1.27 | Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine. ( Kuroda, H; Nukina, I; Ogawa, N; Ota, Z; Yamamoto, M, 1984) |
| "Benserazide was combined with carbidopa in 38 patients who were experiencing a diminished response to carbidopa, including 22 patients with diurnal oscillations in performance, "wearing off" or on-off phenomena." | 1.27 | Combined use of benserazide and carbidopa in Parkinson's disease. ( Goldstein, M; Gopinathan, G; Hiesiger, E; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R, 1984) |
| "Four cases of dystonia occurring in two families are reported." | 1.27 | Dystonia--L-dopa responsive or juvenile parkinsonism? ( Rondot, P; Ziegler, M, 1983) |
| "A number of patients with Parkinson's disease complain of severe and distressing pain." | 1.27 | Painful Parkinson's disease. ( Koller, WC; Lang, AE; Marsden, CD; Quinn, NP, 1986) |
| "In addition the time from the onset of Parkinson's disease to significantly longer in the group of patients which were treated with Madopar and (-)deprenyl in combination." | 1.27 | Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience. ( Birkmayer, GD; Birkmayer, W, 1986) |
| " In 13 patients a considerable diminution in nocturnal akinesia and in the frequency of waking up was reached with a mean dosage of 308 mg of Madopar HBS." | 1.27 | Madopar HBS in Parkinson patients with nocturnal akinesia. ( Jansen, EN; Meerwaldt, JD, 1988) |
| " At the end of the dosage adaptation phase (9 weeks) most patients improved; in patients with 'on-off' phenomenon, parkinsonism became less severe, on periods were longer, and fluctuations decrease; end-of-dose impairment resolved in 4 patients." | 1.27 | Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations. ( Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A, 1987) |
| " The dosage was adjusted until optimal response was obtained." | 1.27 | Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment. ( Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO, 1987) |
| " In all patients of the first group, after 3 months on stable 'optimal' dosage schedule, the previous L-dopa treatment was abruptly replaced, dose for dose, from one day to another by Madopar HBS, a new controlled-release form of Madopar." | 1.27 | Therapeutic value of Madopar HBS: judgment after 2 years experience. ( Siegfried, J, 1987) |
| " In nine subjects who completed the trial, the clinical response, occurrence of dyskinesias and of nausea and vomiting, were similar with both treatments, although peak plasma levodopa concentration and levodopa bioavailability were greater on levodopa-domperidone than on levodopa-carbidopa." | 1.27 | Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease. ( Langdon, N; Malcolm, PN; Parkes, JD, 1986) |
| "Levodopa treatment alleviated the parkinsonian symptoms to a considerable degree and substantially improved the quality of life of the parkinsonian patients." | 1.26 | Long-term responses of Parkinson's disease to levodopa therapy. ( Marttila, R; Rinne, UK; Siirtola, T; Sonninen, V, 1980) |
| "Levodopa 40 mg was taken at intervals of half to two and a half hours, usually with benserazide 10 mg but alone in the late morning and evening." | 1.26 | Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide. ( Dean, BC; McLellan, DL, 1982) |
| " PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients." | 1.26 | Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. ( Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S, 1982) |
| "CDP-choline treatment showed a significant improvement of rigidity and bradykinesia and a less important amelioration of tremor." | 1.26 | New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline). ( Agnoli, A; Bruno, G; Denaro, A; Ruggieri, S, 1982) |
| " Reduction of levodopa dosage to one sixth with the aid of a peripheral decarboxylase inhibitor (benserazide) largely eliminated autoimmune haemolysis while maintaining adequate control of neurologic symptoms." | 1.26 | Dose-related levodopa-induced haemolytic anaemia. ( Enström, MS; Liedén, G; Linström, FD, 1977) |
| "Twenty-six patients affected by Parkinson's disease were treated with a 2-Br-alpha-ergocriptine (CB 154): 14 cases were given CB 154 alone, and 12 were given CB 154 along with L-dopa plus benserazide (Madopar)." | 1.26 | Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease. ( Caraceni, TA; Celano, I; Girotti, F; Parati, E, 1977) |
| "Levodopa treatment, alone or in combination with two different dopa-decarboxylase inhibitors, benserazide and carbidopa, does not modify the renin response to posture or to frusemide." | 1.26 | Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease. ( Dessi'-Fulgheri, P; Glorioso, N; Monaco, F; Rappelli, A; Tedde, R, 1978) |
| "A patient with Parkinson's disease, in whom polycythemia vera was known to be present for several years prior to the onset of parkinsonian symptoms, received treatment with a preparation consisting of L-dopa plus a decarboxylase inhibitor (Madopar)." | 1.26 | Effect of L-dopa on polycythemia. ( Herishanu, Y; Rosenberg, P, 1977) |
| "Since L-dopa in combination with a decarboxylase inhibitor is currently the most effective therapy available for treatment of Parkinson's disease, the authors compare the actual causes of death in a large series of treated Parkinson patients with a normal population and with previous studies." | 1.26 | Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. ( Siegfried, J; Zumstein, H, 1976) |
| " A reduced mean L-Dopa dosage was ruled out as the cause of this deterioration." | 1.26 | Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor. ( Bass-Verrey, F; Ludin, HP, 1976) |
| " The adverse effect reappeared in a more severe and prolonged form when she was treated one year later with levodopa in combination with the peripheral decarboxylase inhibitor Ro-4-4602." | 1.26 | Prolonged symptoms of brain dysfunction--adverse effect of levodopa. ( Anggård, E; Samuelsson, K, 1976) |
| "Eighty-one Parkinsonic patients were treated with L-dopa alone and/or combined with Ro4-4602, during 27 to 60 months." | 1.26 | [5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602]. ( Chouza, C; Gomensoro, JB; Romero, S, 1976) |
| "Levodopa induced an increase of about 400 fold in urinary DA; DOPAC was increased about 300 fold, 3-MT only about 70 fold, but HVA about 300 fold." | 1.25 | Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. ( Rinne, UK; Siirtola, T; Sonninen, V, 1975) |
| " Observations were repeated with varying dosage patterns, showing variations but no substantial changes or disappearance of the symptoms described." | 1.25 | [Long-term syndrome in the treatment of parkinsonism with L-dopa]. ( Chouza, C; Gomensoro, JB; Romero, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 168 (49.41) | 18.7374 |
| 1990's | 71 (20.88) | 18.2507 |
| 2000's | 34 (10.00) | 29.6817 |
| 2010's | 59 (17.35) | 24.3611 |
| 2020's | 8 (2.35) | 2.80 |
| Authors | Studies |
|---|---|
| Daidone, F | 1 |
| Montioli, R | 1 |
| Paiardini, A | 1 |
| Cellini, B | 1 |
| Macchiarulo, A | 1 |
| Giardina, G | 1 |
| Bossa, F | 1 |
| Borri Voltattorni, C | 1 |
| Banerjee, A | 1 |
| Patil, S | 1 |
| Pawar, MY | 1 |
| Gullapalli, S | 1 |
| Gupta, PK | 1 |
| Gandhi, MN | 1 |
| Bhateja, DK | 1 |
| Bajpai, M | 1 |
| Sangana, RR | 1 |
| Gudi, GS | 1 |
| Khairatkar-Joshi, N | 1 |
| Gharat, LA | 1 |
| Baba, Y | 1 |
| Futamura, A | 1 |
| Kinno, R | 1 |
| Nomoto, S | 1 |
| Takahashi, S | 1 |
| Yasumoto, T | 1 |
| Osakabe, Y | 1 |
| Shoji, D | 1 |
| Nabeshima, Y | 1 |
| Su, D | 1 |
| Su, Y | 1 |
| Xu, B | 1 |
| Chhetri, JK | 1 |
| Chan, P | 3 |
| Murakami, Y | 1 |
| Nishijima, H | 1 |
| Nakamura, T | 3 |
| Furukawa, T | 1 |
| Kinoshita, I | 1 |
| Kon, T | 1 |
| Suzuki, C | 1 |
| Tomiyama, M | 1 |
| Yang, Y | 1 |
| Gao, F | 1 |
| Gao, L | 1 |
| Miao, J | 1 |
| van Nuland, AJ | 1 |
| Helmich, RC | 2 |
| Dirkx, MF | 2 |
| Zach, H | 2 |
| Toni, I | 1 |
| Cools, R | 1 |
| den Ouden, HEM | 1 |
| Santos, MEHP | 1 |
| Olops, L | 1 |
| Vendrame, F | 1 |
| Tavares, AHJ | 1 |
| Leonardo, DP | 1 |
| de Azevedo, PC | 1 |
| Piovesana, LG | 1 |
| Costa, FF | 1 |
| Fertrin, KY | 1 |
| Ong, TL | 1 |
| Dal, S | 1 |
| Martin, AJ | 1 |
| Chang, FC | 1 |
| Williams, LJ | 1 |
| Babu, S | 1 |
| Mahant, N | 1 |
| Morales-Briceno, H | 1 |
| Fletcher, N | 1 |
| Nankervis, J | 1 |
| Robbie, M | 1 |
| Fung, VSC | 1 |
| Jiang, DQ | 1 |
| Zang, QM | 1 |
| Jiang, LL | 1 |
| Wang, Y | 3 |
| Li, MX | 1 |
| Qiao, JY | 1 |
| Seiffert, P | 1 |
| Derejczyk, J | 1 |
| Kawa, J | 1 |
| Marcisz, C | 1 |
| Czernek, M | 1 |
| Szymszal, J | 1 |
| Kapko, W | 1 |
| Bugdol, M | 1 |
| Torbus, A | 1 |
| Stępień-Wyrobiec, O | 1 |
| Cilia, R | 1 |
| Laguna, J | 1 |
| Cassani, E | 1 |
| Cereda, E | 1 |
| Pozzi, NG | 3 |
| Isaias, IU | 3 |
| Contin, M | 5 |
| Barichella, M | 1 |
| Pezzoli, G | 5 |
| Yoosefian, M | 1 |
| Rahmanifar, E | 1 |
| Etminan, N | 1 |
| Lee, HD | 1 |
| Chang, MC | 1 |
| Bloem, BR | 1 |
| Hallett, M | 2 |
| Turco, F | 1 |
| Canessa, A | 2 |
| Olivieri, C | 1 |
| Palmisano, C | 2 |
| Arnulfo, G | 1 |
| Marotta, G | 1 |
| Volkmann, J | 2 |
| Chandel, TI | 1 |
| Zaidi, N | 1 |
| Zaman, M | 1 |
| Jahan, I | 1 |
| Masroor, A | 1 |
| Siddique, IA | 1 |
| Nayeem, SM | 1 |
| Ali, M | 1 |
| Uversky, VN | 1 |
| Khan, RH | 1 |
| Brandt, G | 1 |
| Leporini, A | 1 |
| Maltese, V | 1 |
| Frigo, CA | 1 |
| Torti, M | 1 |
| Alessandroni, J | 1 |
| Bravi, D | 1 |
| Casali, M | 1 |
| Grassini, P | 1 |
| Fossati, C | 1 |
| Ialongo, C | 1 |
| Onofrj, M | 1 |
| Radicati, FG | 1 |
| Vacca, L | 1 |
| Bonassi, S | 1 |
| Stocchi, F | 6 |
| Gasser, UE | 3 |
| Fischer, A | 1 |
| Timmermans, JP | 1 |
| Arnet, I | 1 |
| Zhang, J | 3 |
| Ma, YZ | 1 |
| Shen, XM | 1 |
| Lopez, S | 1 |
| Bonito-Oliva, A | 1 |
| Pallottino, S | 1 |
| Acher, F | 1 |
| Fisone, G | 1 |
| Almeida, KJ | 1 |
| de Oliveira Filho, MC | 1 |
| Lopes Nery, PC | 1 |
| Guimarães Silva, JS | 1 |
| Campos Sousa, RN | 1 |
| Aquino, CC | 1 |
| Celso de Castro, P | 1 |
| Doná, F | 1 |
| Medeiros, L | 1 |
| Silva, SM | 1 |
| Borges, V | 1 |
| Ferraz, HB | 1 |
| Porras, G | 1 |
| De Deurwaerdere, P | 1 |
| Li, Q | 1 |
| Marti, M | 2 |
| Morgenstern, R | 1 |
| Sohr, R | 1 |
| Bezard, E | 1 |
| Morari, M | 2 |
| Meissner, WG | 1 |
| Hattori, N | 1 |
| Solís, O | 1 |
| Espadas, I | 1 |
| Del-Bel, EA | 1 |
| Moratalla, R | 1 |
| Xie, CL | 1 |
| Wang, WW | 1 |
| Zhang, SF | 1 |
| Yuan, ML | 1 |
| Che, JY | 1 |
| Gan, J | 1 |
| Song, L | 1 |
| Yuan, WE | 1 |
| Liu, ZG | 1 |
| Ferreira, JJ | 3 |
| Rocha, JF | 3 |
| Falcão, A | 2 |
| Santos, A | 2 |
| Pinto, R | 2 |
| Nunes, T | 3 |
| Soares-da-Silva, P | 4 |
| Alirezaei, M | 1 |
| Khoshdel, Z | 1 |
| Dezfoulian, O | 1 |
| Rashidipour, M | 1 |
| Taghadosi, V | 1 |
| Gellhaar, S | 1 |
| Marcellino, D | 1 |
| Abrams, MB | 1 |
| Galter, D | 1 |
| Epprecht, L | 1 |
| Schreglmann, SR | 1 |
| Goetze, O | 1 |
| Woitalla, D | 3 |
| Baumann, CR | 1 |
| Waldvogel, D | 1 |
| Shan, L | 1 |
| Diaz, O | 1 |
| Zhang, Y | 1 |
| Ladenheim, B | 1 |
| Cadet, JL | 1 |
| Chiang, YH | 1 |
| Olson, L | 1 |
| Hoffer, BJ | 1 |
| Bäckman, CM | 1 |
| Pan, X | 1 |
| Chen, C | 1 |
| Huang, J | 1 |
| Wei, H | 1 |
| Fan, Q | 1 |
| Song, JH | 1 |
| Zhou, PY | 1 |
| Cao, ZH | 1 |
| Ding, ZG | 1 |
| Chen, HX | 1 |
| Zhang, GB | 1 |
| Michel, A | 1 |
| Downey, P | 1 |
| Van Damme, X | 1 |
| De Wolf, C | 1 |
| Schwarting, R | 1 |
| Scheller, D | 1 |
| Kuoppamäki, M | 2 |
| Leinonen, M | 2 |
| Poewe, W | 6 |
| Wu, T | 1 |
| Feng, T | 2 |
| Hou, Y | 2 |
| Calandra-Buonaura, G | 1 |
| Doria, A | 1 |
| Lopane, G | 1 |
| Guaraldi, P | 1 |
| Capellari, S | 1 |
| Martinelli, P | 4 |
| Cortelli, P | 1 |
| Guo, Z | 1 |
| Xu, S | 2 |
| Du, N | 1 |
| Liu, J | 1 |
| Huang, Y | 2 |
| Han, M | 1 |
| Bang, JI | 1 |
| Jung, IS | 1 |
| Song, YS | 1 |
| Park, HS | 1 |
| Moon, BS | 1 |
| Lee, BC | 1 |
| Kim, SE | 1 |
| Almeida, L | 2 |
| Gonzalez-Maldonado, R | 1 |
| Gonzalez-Redondo, R | 1 |
| Di Caudo, C | 1 |
| Guo, G | 1 |
| Cao, LD | 1 |
| Wu, QY | 1 |
| Geng, X | 1 |
| Wang, X | 2 |
| Xie, J | 1 |
| Zhang, X | 1 |
| Lei, C | 1 |
| Li, M | 3 |
| Han, H | 1 |
| Yao, X | 1 |
| Zhang, Q | 1 |
| Wang, M | 1 |
| Adams, F | 1 |
| Boschmann, M | 1 |
| Lobsien, E | 1 |
| Kupsch, A | 1 |
| Lipp, A | 1 |
| Franke, G | 1 |
| Leisse, MC | 1 |
| Janke, J | 1 |
| Gottschalk, S | 1 |
| Spranger, J | 1 |
| Jordan, J | 1 |
| Fung, VS | 1 |
| Herawati, L | 1 |
| Wan, Y | 1 |
| Li, W | 1 |
| Lu, L | 1 |
| Shi, W | 1 |
| Ren, XM | 1 |
| Cannas, A | 2 |
| Solla, P | 2 |
| Floris, G | 2 |
| Tacconi, P | 2 |
| Serra, A | 1 |
| Piga, M | 1 |
| Marrosu, F | 1 |
| Marrosu, MG | 1 |
| Wang, HB | 1 |
| Hsu, CH | 1 |
| Jiang, X | 1 |
| Zhuo, Y | 1 |
| Tang, A | 1 |
| Wik, G | 1 |
| Eggert, K | 2 |
| Skogar, O | 1 |
| Amar, K | 1 |
| Luotonen, L | 1 |
| Nissinen, H | 1 |
| Oertel, W | 1 |
| Adamiak, U | 1 |
| Kaldonska, M | 1 |
| Klodowska-Duda, G | 1 |
| Wyska, E | 1 |
| Safranow, K | 1 |
| Bialecka, M | 1 |
| Gawronska-Szklarz, B | 1 |
| Kobylecki, C | 1 |
| Cenci, MA | 1 |
| Crossman, AR | 1 |
| Ravenscroft, P | 1 |
| Müller, T | 6 |
| Muhlack, S | 5 |
| Ries, V | 1 |
| Selzer, R | 2 |
| Eichhorn, T | 1 |
| Oertel, WH | 3 |
| Stefanis, N | 1 |
| Bozi, M | 1 |
| Christodoulou, C | 1 |
| Douzenis, A | 1 |
| Gasparinatos, G | 1 |
| Stamboulis, E | 1 |
| Stefanis, C | 1 |
| Stefanis, L | 1 |
| Rascol, O | 2 |
| Sampaio, C | 1 |
| Prakash, KM | 1 |
| Kek, PC | 1 |
| Tani, Y | 1 |
| Ogata, A | 1 |
| Koyama, M | 1 |
| Inoue, T | 1 |
| Gil, SJ | 1 |
| Park, CH | 1 |
| Lee, JE | 1 |
| Minn, YK | 1 |
| Koh, HC | 1 |
| Dick, OE | 1 |
| Romanov, SP | 1 |
| Nozdrachev, AD | 1 |
| Hashim, HZ | 1 |
| Wan Musa, WR | 1 |
| Ngiu, CS | 1 |
| Wan Yahya, WN | 1 |
| Tan, HJ | 1 |
| Ibrahim, N | 1 |
| Adam, JJ | 1 |
| van Houdt, H | 1 |
| Scholtissen, B | 1 |
| Visser-Vandewalle, V | 1 |
| Winogrodzka, A | 1 |
| Duits, A | 1 |
| Geiser, E | 1 |
| Kaelin-Lang, A | 1 |
| Ishihara, A | 1 |
| Miyachi, T | 1 |
| Ohtsuki, T | 1 |
| Kimura, Y | 1 |
| Kihira, K | 1 |
| Yamawaki, T | 1 |
| Matsumoto, M | 1 |
| Yang, MH | 2 |
| Li, SD | 1 |
| Liu, Y | 2 |
| Costa, C | 1 |
| Sgobio, C | 1 |
| Siliquini, S | 1 |
| Tozzi, A | 1 |
| Tantucci, M | 1 |
| Ghiglieri, V | 1 |
| Di Filippo, M | 1 |
| Pendolino, V | 1 |
| de Iure, A | 1 |
| Spillantini, MG | 1 |
| Latagliata, EC | 1 |
| Pascucci, T | 1 |
| Puglisi-Allegra, S | 1 |
| Gardoni, F | 1 |
| Di Luca, M | 1 |
| Picconi, B | 1 |
| Calabresi, P | 1 |
| Gerlach, M | 2 |
| Halley, P | 1 |
| Riederer, P | 6 |
| van den Buuse, M | 1 |
| El Otmani, H | 1 |
| Moutaouakil, F | 1 |
| Fadel, H | 1 |
| Slassi, I | 1 |
| Zavala, JA | 1 |
| Munhoz, RP | 1 |
| Teive, HA | 1 |
| Grandas, FJ | 1 |
| Sesar-Ignacio, Á | 1 |
| Iskedjian, M | 1 |
| Einarson, TR | 1 |
| Shen, H | 1 |
| Kannari, K | 1 |
| Yamato, H | 1 |
| Arai, A | 1 |
| Matsunaga, M | 1 |
| Scaglione, C | 1 |
| Riva, R | 3 |
| Albani, F | 2 |
| Baruzzi, A | 3 |
| Yoshida, T | 1 |
| Kono, I | 1 |
| Yoshikawa, K | 1 |
| Hashimoto, H | 1 |
| Harada, H | 1 |
| Nakagawa, M | 1 |
| Welnic, J | 3 |
| Twiehaus, S | 1 |
| Przuntek, H | 6 |
| Mochi, M | 1 |
| Ludin, HP | 3 |
| St-Hilaire, M | 1 |
| Bourhis, E | 1 |
| Lévesque, D | 1 |
| Rouillard, C | 1 |
| Fleming, SM | 1 |
| Salcedo, J | 1 |
| Hutson, CB | 1 |
| Rockenstein, E | 1 |
| Masliah, E | 1 |
| Levine, MS | 1 |
| Chesselet, MF | 1 |
| Chen, XH | 1 |
| Li, Y | 1 |
| Kui, Y | 1 |
| Lian, XF | 1 |
| Luo, XD | 1 |
| Pinessi, L | 1 |
| Sabbatini, F | 1 |
| De Mattei, M | 1 |
| Gentile, S | 1 |
| Fischer, PA | 4 |
| Majer, M | 1 |
| Welzel, D | 2 |
| Kandel', EI | 1 |
| Iadgarov, IS | 1 |
| Birkmayer, W | 8 |
| Birkmayer, G | 1 |
| Lechner, H | 1 |
| Fekete, M | 1 |
| Tárczy, M | 4 |
| Bihari, K | 1 |
| Katona, G | 2 |
| Csanda, E | 3 |
| Takáts, A | 2 |
| Mogyorós, I | 1 |
| Köves, A | 1 |
| Gerstenbrand, F | 1 |
| Ransmayr, G | 2 |
| Ogawa, N | 1 |
| Kuroda, H | 1 |
| Yamamoto, M | 2 |
| Nukina, I | 1 |
| Ota, Z | 1 |
| Da Prada, M | 2 |
| Keller, HH | 1 |
| Pieri, L | 1 |
| Kettler, R | 1 |
| Haefely, WE | 1 |
| Martinez-Campos, A | 3 |
| Giovannini, P | 4 |
| Cocchi, D | 2 |
| Zanardi, P | 1 |
| Parati, EA | 1 |
| Caraceni, T | 4 |
| Müller, EE | 3 |
| Lieberman, AN | 2 |
| Goldstein, M | 2 |
| Gopinathan, G | 2 |
| Neophytides, A | 1 |
| Hiesiger, E | 1 |
| Walker, R | 1 |
| Nelson, J | 1 |
| Rondot, P | 6 |
| Ziegler, M | 3 |
| Baldassarre, G | 1 |
| Fazio, B | 1 |
| Vogel, HP | 2 |
| Schiffter, R | 1 |
| Ulm, G | 1 |
| Gerdes, U | 1 |
| Lehmann, K | 1 |
| Agnoli, A | 5 |
| Ruggieri, S | 6 |
| Baldassarre, M | 2 |
| Rocco, A | 2 |
| Del Roscio, S | 1 |
| D'Urso, R | 2 |
| Mearelli, S | 1 |
| Falaschi, P | 2 |
| Frajese, G | 1 |
| Rinne, UK | 11 |
| Sonninen, V | 4 |
| Siirtola, T | 4 |
| Marttila, R | 3 |
| Liu, DK | 3 |
| Lavin, PJ | 1 |
| Gawel, MJ | 1 |
| Das, PK | 1 |
| Alaghband-Zadeh, J | 1 |
| Rose, FC | 1 |
| Young, SN | 1 |
| Gauthier, S | 1 |
| Chouinard, G | 1 |
| Anderson, GM | 1 |
| Purdy, WC | 1 |
| McLellan, DL | 1 |
| Dean, BC | 1 |
| Novelli, A | 2 |
| Ando, K | 1 |
| De Giorgio, G | 1 |
| Hildick-Smith, M | 1 |
| Denaro, A | 1 |
| Bruno, G | 1 |
| Parati, E | 2 |
| Hagan, RM | 1 |
| Raxworthy, MJ | 1 |
| Gulliver, PA | 1 |
| Boomsma, F | 3 |
| van den Meiracker, A | 1 |
| Man in 't Veld, A | 1 |
| Schalekamp, M | 1 |
| Fernández Pardal, MM | 1 |
| Gatto, E | 1 |
| Micheli, F | 1 |
| Casas Parera, I | 1 |
| Diaz, S | 1 |
| Dessibourg, CA | 1 |
| Gachoud, JP | 2 |
| Sieradzan, K | 1 |
| Channon, S | 1 |
| Ramponi, C | 1 |
| Stern, GM | 2 |
| Lees, AJ | 6 |
| Youdim, MB | 2 |
| Fonda, D | 1 |
| Schwarz, J | 1 |
| Clinnick, S | 1 |
| Milandre, L | 1 |
| Khalil, R | 1 |
| Schmid, PA | 1 |
| Suter, T | 1 |
| Speich, R | 1 |
| Eberli, F | 1 |
| Greminger, P | 1 |
| Bergemann, N | 1 |
| Baas, H | 4 |
| Tison, F | 1 |
| Duché, B | 1 |
| Loiseau, P | 1 |
| Bächli, E | 1 |
| Albani, C | 4 |
| Klockgether, T | 1 |
| Dichgans, J | 2 |
| Date, I | 1 |
| Yoshimoto, Y | 1 |
| Imaoka, T | 1 |
| Miyoshi, Y | 1 |
| Furuta, T | 1 |
| Asari, S | 1 |
| Ohmoto, T | 1 |
| Pinter, MM | 1 |
| Helscher, RJ | 1 |
| Chia, LG | 1 |
| Cheng, FC | 1 |
| Kuo, JS | 1 |
| Atchison, PR | 1 |
| Thompson, PD | 1 |
| Frackowiak, RS | 1 |
| Marsden, CD | 6 |
| Chanter, DO | 1 |
| Buck, A | 1 |
| Imai, H | 1 |
| Kondo, T | 5 |
| Narabayashi, H | 4 |
| Linazasoro, G | 1 |
| Martí Massó, JF | 1 |
| Suárez, JA | 1 |
| Weller, C | 1 |
| O'Neill, CJ | 1 |
| Charlett, A | 1 |
| Bowes, SG | 1 |
| Purkiss, A | 1 |
| Nicholson, PW | 1 |
| Dobbs, RJ | 1 |
| Dobbs, SM | 1 |
| Gorchein, A | 1 |
| Eichhorn, TE | 1 |
| Schrag, A | 1 |
| Trenkwalder, C | 1 |
| Kohnen, R | 1 |
| Henderson, JM | 3 |
| Einstein, R | 2 |
| Jackson, DM | 1 |
| Byth, K | 2 |
| Morris, JG | 3 |
| Bayülkem, K | 1 |
| Erişir, K | 1 |
| Tuncel, A | 1 |
| Bayülkem, B | 1 |
| Limousin, P | 1 |
| Pollak, P | 1 |
| Pfefen, JP | 1 |
| Tournier-Gervason, CL | 1 |
| Dubuis, R | 1 |
| Perret, JE | 1 |
| Dupont, E | 6 |
| Andersen, A | 1 |
| Boas, J | 1 |
| Boisen, E | 1 |
| Borgmann, R | 1 |
| Helgetveit, AC | 1 |
| Kjaer, MO | 1 |
| Kristensen, TN | 1 |
| Mikkelsen, B | 6 |
| Pakkenberg, H | 4 |
| Presthus, J | 3 |
| Stien, R | 1 |
| Worm-Petersen, J | 1 |
| Buch, D | 1 |
| Marin, C | 1 |
| Papa, S | 1 |
| Engber, TM | 1 |
| Bonastre, M | 1 |
| Tolosa, E | 1 |
| Chase, TN | 1 |
| Shan, DE | 1 |
| Yeh, SI | 1 |
| Ghika, J | 2 |
| Gasser, U | 1 |
| Merello, M | 1 |
| Pikielny, R | 1 |
| Cammarota, A | 1 |
| Leiguarda, R | 1 |
| Fuh, JL | 1 |
| Lee, RC | 1 |
| Wang, SJ | 1 |
| Lin, CH | 1 |
| Wang, PN | 1 |
| Chiang, JH | 1 |
| Liu, HC | 1 |
| Arai, H | 1 |
| Shinotoh, H | 1 |
| Hattori, T | 1 |
| Lyytinen, J | 1 |
| Kaakkola, S | 1 |
| Ahtila, S | 1 |
| Tuomainen, P | 1 |
| Teräväinen, H | 1 |
| Yiannikas, C | 2 |
| Jackson, D | 1 |
| Patsalos, PN | 1 |
| Berardelli, A | 1 |
| Barbato, L | 1 |
| Bonamartini, A | 1 |
| Manfredi, M | 1 |
| Hagell, P | 1 |
| Odin, P | 1 |
| Vinge, E | 1 |
| Leiva, C | 1 |
| Goetz, CG | 1 |
| Beiske, AG | 1 |
| Jackson, M | 1 |
| Harder, S | 1 |
| Jorga, KM | 1 |
| Larsen, JP | 1 |
| Beiske, A | 1 |
| Schleimer, M | 1 |
| Fotteler, B | 2 |
| Schmitt, M | 1 |
| Moe, B | 1 |
| Jorga, K | 2 |
| Crevoisier, C | 1 |
| Hovens, SE | 1 |
| van Giersbergen, PL | 1 |
| Dizdar, N | 1 |
| Granérus, AK | 1 |
| Hannestad, U | 1 |
| Kullman, A | 1 |
| Ljungdahl, A | 1 |
| Olsson, JE | 1 |
| Kågedal, B | 1 |
| Banken, L | 1 |
| Snell, P | 1 |
| Steimer, JL | 1 |
| Castiello, U | 1 |
| Bennett, KM | 1 |
| Bonfiglioli, C | 1 |
| Peppard, RF | 1 |
| Parada, A | 1 |
| Serrão, P | 1 |
| Routiot, T | 1 |
| Lurel, S | 1 |
| Denis, E | 1 |
| Barbarino-Monnier, P | 1 |
| Vendrova, MI | 1 |
| Sadekov, RA | 1 |
| Golubev, VL | 1 |
| Brüne, M | 1 |
| Gerlach, G | 1 |
| Schröder, SG | 1 |
| Descombes, S | 1 |
| Bonnet, AM | 2 |
| Thalamas, C | 1 |
| Dingemanse, J | 1 |
| Arnulf, I | 1 |
| Bareille, MP | 1 |
| Agid, Y | 3 |
| Datla, KP | 1 |
| Blunt, SB | 1 |
| Dexter, DT | 1 |
| Jonkers, N | 1 |
| Sarre, S | 1 |
| Ebinger, G | 2 |
| Michotte, Y | 1 |
| Benz, S | 1 |
| Börnke, C | 1 |
| Burkhard, P | 1 |
| Dominici, P | 1 |
| Borri-Voltattorni, C | 1 |
| Jansonius, JN | 1 |
| Malashkevich, VN | 1 |
| Hironishi, M | 1 |
| Miwa, H | 1 |
| Casacchia, M | 1 |
| Carolei, A | 1 |
| Zamponi, A | 1 |
| Fazio, C | 1 |
| Birket-Smith, E | 3 |
| Hansen, E | 4 |
| Hyyppä, M | 1 |
| Ambrozi, L | 1 |
| Greenacre, JK | 1 |
| Coxon, A | 1 |
| Petrie, A | 1 |
| Reid, JL | 1 |
| Yahr, MD | 2 |
| Barbeau, A | 3 |
| Campanella, G | 3 |
| Butterworth, RF | 1 |
| Yamada, K | 1 |
| Gilland, O | 1 |
| Battistin, L | 1 |
| Meneghetti, G | 1 |
| Rigotti, S | 1 |
| Saia, A | 1 |
| Diamond, SG | 1 |
| Markham, CH | 1 |
| Treciokas, LJ | 1 |
| Williams, BO | 1 |
| Carlyle, D | 1 |
| Linström, FD | 1 |
| Liedén, G | 1 |
| Enström, MS | 1 |
| Martin, S | 1 |
| Yokochi, M | 2 |
| Hirayama, K | 2 |
| Kuruma, I | 2 |
| Podiwinsky, F | 1 |
| Mentasti, M | 2 |
| Bender, DA | 1 |
| Earl, CJ | 1 |
| Conte, P | 1 |
| Moulinier, J | 1 |
| Reiffers, J | 1 |
| Julien, J | 1 |
| Lieberman, A | 1 |
| Estey, E | 1 |
| Ohashi, T | 1 |
| Sauter, A | 1 |
| Mölsä, P | 1 |
| Caraceni, TA | 1 |
| Celano, I | 1 |
| Girotti, F | 1 |
| Shau-Fong, K | 1 |
| Ho, YM | 1 |
| Feuerstein, C | 2 |
| Serre, F | 2 |
| Gavend, M | 2 |
| Pellat, J | 2 |
| Perret, J | 2 |
| Tanche, M | 2 |
| Rappelli, A | 1 |
| Glorioso, N | 1 |
| Tedde, R | 1 |
| Dessi'-Fulgheri, P | 1 |
| Monaco, F | 1 |
| Clemens, R | 1 |
| Gerlach, J | 1 |
| Pinder, RM | 1 |
| Brogden, RN | 1 |
| Sawyer, PR | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Lakke, JP | 1 |
| Bissessur, S | 1 |
| De Man, JJ | 1 |
| Moll, L | 1 |
| Seegers, J | 1 |
| Wesseling, H | 1 |
| Witt, FG | 1 |
| Chouza, C | 8 |
| Romero, S | 8 |
| Gomensoro, JB | 4 |
| Markianos, ES | 1 |
| Rüther, E | 2 |
| Herishanu, Y | 1 |
| Rosenberg, P | 1 |
| Slome, R | 1 |
| Algeri, S | 1 |
| Cerletti, C | 1 |
| Dolfini, E | 1 |
| Jori, A | 1 |
| Rinaldi, F | 1 |
| Lhermitte, F | 2 |
| Signoret, JL | 1 |
| Studler, JM | 1 |
| Roy, M | 1 |
| Zumstein, H | 1 |
| Siegfried, J | 3 |
| Johnson, RD | 1 |
| Ruthven, CR | 1 |
| Goodwin, BL | 1 |
| Sandler, M | 1 |
| Bass-Verrey, F | 1 |
| Samuelsson, K | 1 |
| Anggård, E | 1 |
| Mizuno, Y | 2 |
| Yoshida, M | 1 |
| Obayashi, T | 1 |
| Ueki, A | 1 |
| Korten, JJ | 2 |
| Keyser, A | 1 |
| Joosten, EM | 1 |
| Gabreëls, FJ | 1 |
| Bathien, N | 1 |
| Dumas, JL | 1 |
| Rautakorpi, I | 1 |
| Riman, E | 1 |
| De Keyser, J | 1 |
| Herroelen, L | 1 |
| Vervaeck, M | 1 |
| Bruyland, M | 1 |
| Schwarzmann, D | 1 |
| Letzel, H | 1 |
| Kraus, PH | 1 |
| Steiger, MJ | 2 |
| Bramante, L | 1 |
| Quinn, NP | 6 |
| Furukawa, Y | 1 |
| Nishi, K | 1 |
| Kleedorfer, B | 1 |
| Jenkins, JR | 1 |
| Pearce, JM | 1 |
| Azuma, T | 1 |
| Suzuki, T | 1 |
| Sakoda, S | 1 |
| Mizuno, R | 1 |
| Tsujino, S | 1 |
| Kobayashi, T | 1 |
| Kishimoto, S | 1 |
| Hiraga, T | 1 |
| Matsubara, T | 1 |
| Yoshida, S | 1 |
| Masson, H | 1 |
| Popescu, I | 1 |
| Strubel, D | 1 |
| Cramer, H | 1 |
| Kuntzmann, F | 1 |
| Tulloch, JA | 1 |
| Ashwood, TJ | 1 |
| Bateman, DN | 1 |
| Woodhouse, KW | 1 |
| Díaz, F | 1 |
| Chaná, P | 1 |
| Tedroff, J | 1 |
| Hartvig, P | 1 |
| Bjurling, P | 1 |
| Andersson, Y | 1 |
| Antoni, G | 1 |
| Långström, B | 1 |
| Russ, H | 1 |
| Dettner, O | 1 |
| Kuhn, W | 3 |
| Graham, JS | 1 |
| Cunningham, MA | 1 |
| Darby, DG | 1 |
| Donnan, GA | 1 |
| Carta, A | 1 |
| Aljanati, R | 4 |
| Caamaño, JL | 4 |
| De Medina, O | 4 |
| Scaramelli, A | 3 |
| Buzó, R | 2 |
| Plachín, V | 1 |
| Fernandez, A | 2 |
| Todman, DH | 1 |
| Oliver, WA | 1 |
| Edwards, RL | 1 |
| Ceballos-Baumann, AO | 1 |
| von Kummer, R | 1 |
| Eckert, W | 1 |
| Weicker, H | 1 |
| MacMahon, DG | 1 |
| Sachdev, D | 1 |
| Boddie, HG | 1 |
| Ellis, CJ | 1 |
| Kendal, BR | 1 |
| Blackburn, NA | 1 |
| Pletscher, A | 1 |
| Jansen, EN | 3 |
| Meerwaldtt, JD | 1 |
| Kostić, VS | 1 |
| Covicković-Sternić, N | 1 |
| Pacchetti, C | 1 |
| Martignoni, E | 1 |
| Sibilla, L | 1 |
| Bruggi, P | 1 |
| Turla, M | 1 |
| Nappi, G | 1 |
| Horstink, MW | 1 |
| Zijlmans, JC | 1 |
| Pasman, JW | 1 |
| Berger, HJ | 1 |
| van't Hof, MA | 1 |
| Dissing, IC | 1 |
| Güttler, F | 1 |
| Lou, H | 1 |
| Gerdes, AM | 1 |
| Lykkelund, C | 1 |
| Rasmussen, V | 1 |
| Kraus, P | 1 |
| Rinne, JO | 1 |
| Dostert, P | 1 |
| Strolin Benedetti, M | 1 |
| Dordain, G | 1 |
| Vernay, D | 1 |
| Johnels, B | 1 |
| Ingvarsson, PE | 1 |
| Thorselius, M | 1 |
| Valls, M | 1 |
| Steg, G | 1 |
| d'Anglejan Chatillon, J | 1 |
| Emskötter, T | 1 |
| Lachenmayer, L | 1 |
| Heidenreich, C | 1 |
| Meerwaldt, JD | 4 |
| Man in 't Veld, AJ | 1 |
| Hovestadt, A | 2 |
| Schalekamp, MA | 2 |
| Allain, H | 1 |
| Bentue-Ferrer, D | 1 |
| Milon, D | 1 |
| Moran, P | 1 |
| Jacquemard, F | 1 |
| Defawe, G | 1 |
| Man in't Veld, AJ | 1 |
| Scholz, E | 1 |
| Koller, WC | 1 |
| Lang, AE | 1 |
| Hacisalihzade, SS | 2 |
| Mansour, M | 1 |
| Tesei, S | 2 |
| Cossutta, E | 2 |
| Ferrante, C | 2 |
| Zecchinelli, A | 2 |
| Scarlato, G | 2 |
| Jensen, NO | 2 |
| Mikkelsen, BO | 2 |
| Ketsche, R | 1 |
| Stern, G | 2 |
| Mondal, BK | 1 |
| Mondal, KN | 1 |
| Birkmayer, GD | 1 |
| Birkmayer, JD | 1 |
| Jellinger, K | 1 |
| Bliesath, H | 1 |
| Aymard, N | 2 |
| Holzer, J | 2 |
| Marion, MH | 3 |
| Malcolm, SL | 1 |
| Jenner, P | 2 |
| Nordera, GP | 1 |
| Lorizio, A | 1 |
| Lion, P | 1 |
| Durisotti, C | 1 |
| D'Andrea, G | 1 |
| Ferro-Milone, F | 1 |
| Poewe, WH | 1 |
| Heersema, T | 1 |
| van Manen, J | 1 |
| Speelman, JD | 1 |
| Grundmann, M | 1 |
| Schimrigk, K | 1 |
| Wermuth, L | 1 |
| Scarmelli, A | 1 |
| Gonzales Panizza, V | 1 |
| Klein, P | 1 |
| Lees, A | 1 |
| Jakobsen, J | 1 |
| Wilson, JA | 1 |
| Langdon, N | 1 |
| Malcolm, PN | 1 |
| Parkes, JD | 1 |
| Asper, R | 1 |
| Baumgartner, G | 1 |
| Kapfhammer, HP | 1 |
| Kuss, HJ | 1 |
| Grassi, MP | 1 |
| Scigliano, G | 1 |
| Piccolo, I | 1 |
| Soliveri, P | 1 |
| Sachs, C | 1 |
| Berglund, B | 1 |
| Kaijser, L | 1 |
| Coelho, H | 1 |
| Azevedo, M | 1 |
| Manso, C | 1 |
| Esteguy, M | 1 |
| Kefalos, J | 1 |
| Admani, AK | 1 |
| Verma, S | 1 |
| Cordingley, GJ | 1 |
| Harris, RI | 1 |
| Zhou, XD | 1 |
| Yu, HZ | 1 |
| Jyoichi, T | 1 |
| Sato, S | 1 |
| Yasuda, K | 1 |
| Kobayashi, M | 1 |
| Shimojyo, S | 1 |
| Ogura, Y | 1 |
| Miyahara, T | 1 |
| Dumas, RJ | 1 |
| Linauer, W | 1 |
| van Rossum, JM | 1 |
| Lombardo, L | 1 |
| de la Garza, R | 1 |
| Ivan-Reynoso, G | 1 |
| Jacobi, P | 1 |
| Schneider, E | 1 |
| Gundelsheimer, W | 1 |
| Pennetta, R | 1 |
| Puca, FM | 1 |
| Megna, GF | 1 |
| Masi, G | 1 |
| Specchio, LM | 1 |
| Boudin, G | 1 |
| Pépin, B | 1 |
| Guillard, A | 1 |
| Fabiani, JM | 1 |
| Haguenau, M | 1 |
| Steinhäusl, H | 1 |
| Dietrichson, P | 1 |
| Gehlen, W | 1 |
| Eisenlohr, JJ | 1 |
| Streifler, M | 1 |
| Vardi, J | 1 |
| Kesten, M | 1 |
| Tissot, R | 2 |
| Bartholini, G | 1 |
| Constantinidis, J | 2 |
| Eisenring, JJ | 1 |
| Geissbühler, F | 1 |
| Yanniotis, G | 1 |
| de Ajuriaguerra, J | 1 |
| Cavagnini, F | 1 |
| Pontiroli, AE | 1 |
| Raggi, U | 1 |
| Peracchi, M | 1 |
| Malinverni, A | 1 |
| Van Wieringen, A | 1 |
| Frigyesi, TL | 1 |
| Schwartz, DE | 1 |
| Jordan, JC | 1 |
| Ziegler, WH | 1 |
| Fujimori, N | 1 |
| Kito, S | 1 |
| Itoga, E | 1 |
| Kosaka, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.[NCT02680977] | Phase 2 | 18 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Comparison of Blood Dopamine Levels in Idiopathic Parkinson's Patients Receiving Levodopa Carbidopa Entacapone or Levodopa Benserazide[NCT06115538] | Phase 4 | 96 participants (Anticipated) | Interventional | 2023-10-01 | Enrolling by invitation | ||
| Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease - Evolution A Monocentric Study to Investigate the Development of Symptoms of Autonomic Dysregulation in Parkinson's Disease[NCT01518751] | 27 participants (Actual) | Observational | 2011-12-31 | Completed | |||
| A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease[NCT01176240] | Phase 3 | 225 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease[NCT01676103] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| The Influence of Sensory Stimuli on Gait Imagery in Patients With Freezing of Gait[NCT01071590] | 45 participants (Actual) | Observational | 2010-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary efficacy endpoint for 306A is the relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~For the change from baseline, negative numbers represent improvement from baseline in OHQ score." (NCT01176240)
Timeframe: Baseline, Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Droxidopa | -2.2 |
| Placebo | -2.1 |
The total number of patient reported falls during the 8 week treatment period (NCT01176240)
Timeframe: Baseline, Week 8
| Intervention | total falls per group (Number) |
|---|---|
| Droxidopa | 79 |
| Placebo | 192 |
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week1
| Intervention | units on a scale (Mean) |
|---|---|
| Droxidopa | -2.3 |
| Placebo | -1.3 |
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 2 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week2
| Intervention | units on a scale (Mean) |
|---|---|
| Droxidopa | -1.9 |
| Placebo | -1.6 |
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 4 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week4
| Intervention | units on a scale (Mean) |
|---|---|
| Droxidopa | -2.0 |
| Placebo | -1.5 |
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 8 minus score at baseline. A negative score indicates an improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Droxidopa | -2.1 |
| Placebo | -1.5 |
"The relative mean change in Orthostatic Hypotension Questionnaire (OHQ) composite score from baseline to end of study. The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe.~For the change from baseline, negative numbers represent improvement from baseline in OHQ score." (NCT01176240)
Timeframe: Baseline, Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| Droxidopa | -2.2 |
| Placebo | -2.0 |
Measure: Lowest standing systolic blood pressure reading of immediately post standing and 3 minutes post standing. Change: standing systolic blood pressure at Week 1 (Visit 4) minus standing systolic blood pressure at baseline. A positive score indicates an improvement in standing systolic blood pressure during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 1
| Intervention | mmHg (Mean) |
|---|---|
| Droxidopa | 6.4 |
| Placebo | 0.7 |
The average number of patient reported falls per week. (NCT01176240)
Timeframe: up to 10 weeks
| Intervention | falls per week (Mean) |
|---|---|
| Droxidopa | 0.4 |
| Placebo | 2.0 |
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at Week 1 minus score at baseline. A negative score indicates improvement in symptoms during the double-blind randomized phase relative to value at baseline. (NCT01176240)
Timeframe: Baseline, Week 1
| Intervention | units on a scale (Mean) |
|---|---|
| Droxidopa | -3.1 |
| Placebo | -1.6 |
19 reviews available for benserazide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; P | 2021 |
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinat | 2014 |
[Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Topics: Aftercare; Ambulatory Care; Antiparkinson Agents; Apomorphine; Benserazide; Carbidopa; Caregivers; D | 2012 |
[Idiopathic Parkinson's disease: practical hints for the treatment].
Topics: Adult; Aged; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Benserazide; Choline | 2005 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bro | 1984 |
Growth hormone secretion in neurological disorders.
Topics: Benserazide; Disease Models, Animal; Dopamine; Growth Hormone; Humans; Huntington Disease; Levodopa; | 1981 |
[Antiparkinsonian drugs (author's transl)].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibit | 1980 |
[Vascular hemi-parkinson disease].
Topics: Aged; Aspirin; Benserazide; Brain Ischemia; Drug Therapy, Combination; Female; Functional Laterality | 1993 |
The syndrome of gait ignition failure: a report of six cases.
Topics: Aged; Benserazide; Brain; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Female; Gai | 1993 |
Pregnancy in Parkinson's disease: a review of the literature and a case report.
Topics: Abnormalities, Drug-Induced; Adjuvants, Pharmaceutic; Adult; Amantadine; Animals; Antiparkinson Agen | 1998 |
[Parkinson's disease and pregnancy: case report and literature review].
Topics: Adult; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodo | 2000 |
Recent advances in research on Parkinsonism.
Topics: Acetylcholinesterase; Adult; Apomorphine; Benserazide; Brain; Bromocriptine; Carbidopa; Dopa Decarbo | 1978 |
Levodopa.
Topics: Benserazide; Drug Interactions; Hepatic Encephalopathy; Humans; Huntington Disease; Levodopa; Melano | 1975 |
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Topics: Benserazide; Binding Sites; Carbidopa; Carboxy-Lyases; Drug Interactions; Humans; Hydrazines; Kineti | 1976 |
New approaches to the treatment of age-related brain disorders.
Topics: Aging; Alzheimer Disease; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Drug | 1991 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkin | 1990 |
R-(-)-deprenyl and parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Benserazide; Clorgyline; Dopamine; Drug Therapy, Combi | 1987 |
[Influencing of Parkinson's syndrome via intervention in the dopamine metabolism].
Topics: Acetylcholine; Action Potentials; Benserazide; Dihydroxyphenylalanine; Dopamine; Drug Combinations; | 1973 |
[Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
Topics: Administration, Oral; Animals; Benserazide; Dihydroxyphenylalanine; Drug Therapy, Combination; Human | 1973 |
96 trials available for benserazide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Age as a risk factor for orthostatic hypotension induced by the levodopa challenge test in patients with Parkinson's disease: Results from a single-center trial.
Topics: Benserazide; Humans; Hypotension, Orthostatic; Levodopa; Parkinson Disease; Risk Factors | 2023 |
Topics: Antiparkinson Agents; Benserazide; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, D | 2017 |
Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
Topics: Adult; Aged; Benserazide; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Drug Combination | 2019 |
Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Topics: Benserazide; Data Interpretation, Statistical; Drug Combinations; Drugs, Chinese Herbal; Humans; Lev | 2013 |
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; | 2015 |
Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.
Topics: Adult; Aged; Appetite; Benserazide; Breath Tests; Caprylates; Dopamine Agents; Drug Combinations; Ga | 2015 |
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Benserazide; Benzothiazoles; Catechols; Dose-Response Relationship, Drug | 2015 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Da | 2015 |
Neural correlates underlying micrographia in Parkinson's disease.
Topics: Aged; Attention; Basal Ganglia; Benserazide; Brain Mapping; Case-Control Studies; Cerebellum; Drug C | 2016 |
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase; Catechol O- | 2016 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catecho | 2009 |
Fifty cases of Parkinson's disease treated by acupuncture combined with madopar.
Topics: Acupuncture Therapy; Aged; Benserazide; Combined Modality Therapy; Drug Combinations; Female; Humans | 2008 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse | 2010 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; | 2010 |
Effect of exercise on reactivity and motor behaviour in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Attention; Basal Ganglia; Benserazide; Dopamine; Dopamine Agents; Execut | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzoph | 2010 |
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Topics: Acetophenones; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catecho | 2010 |
[Effects of bushenhuoxue granules on sleep quality in Parkinson's patients].
Topics: Aged; Aged, 80 and over; Benserazide; Double-Blind Method; Drug Combinations; Drugs, Chinese Herbal; | 2011 |
[Effects of "attenuation and synergia" for Bushenhuoxue Granules on Parkinson's patients].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Constipation; Doub | 2012 |
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Biological A | 2004 |
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Catechol O-Methyltr | 2005 |
Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Down-Regulation; Enzyme Inhibitors; Humans; Hydrocortisone; | 2007 |
[Clinical observation on abdominal acupuncture plus Madopa for treatment of Parkinson's disease].
Topics: Abdomen; Acupuncture Therapy; Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; | 2007 |
[Effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa].
Topics: Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinations; D | 2007 |
Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
Topics: Adult; Aged; Antiemetics; Antiparkinson Agents; Benserazide; Domperidone; Drug Administration Schedu | 2008 |
[Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
Topics: Aged; Benserazide; Bromocriptine; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combinati | 1984 |
[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Topics: Adult; Aged; Benserazide; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Movement D | 1991 |
The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Topics: Adult; Affect; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Benzamides; Cognition; Dr | 1995 |
[Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Femal | 1994 |
Visual control of arm movement in Parkinson's disease.
Topics: Adult; Aged; Attention; Benserazide; Bromocriptine; Drug Therapy, Combination; Female; Humans; Levod | 1994 |
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Delayed-Ac | 1993 |
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Cause of Death; Disability Evaluation; Drug Admini | 1995 |
'Atypical' tremor.
Topics: Benserazide; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug Combinations; El | 1995 |
A study on the effect and tolerance of lisuride on Parkinson's disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Disease Progression; Drug Therapy, Combinatio | 1996 |
Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dos | 1995 |
Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Denmark; Dose-Response Relatio | 1996 |
An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
Topics: Aged; Antiparkinson Agents; Benserazide; Cross-Over Studies; Dose-Response Relationship, Drug; Drug | 1996 |
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 1997 |
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
Topics: Administration, Oral; Antiparkinson Agents; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitor | 1997 |
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase Inhibito | 1997 |
Postural tremor of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Electromyography; Female; Humans; Levodopa; Male; Mi | 1994 |
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dia | 1998 |
The effect of tolcapone on the pharmacokinetics of benserazide.
Topics: Aged; Antiparkinson Agents; Benserazide; Benzophenones; Dose-Response Relationship, Drug; Drug Admin | 1999 |
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
Topics: Adolescent; Adult; Antiparkinson Agents; Benserazide; Benzophenones; Catechol O-Methyltransferase; C | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benser | 2000 |
[Efficiency of new forms of madopar in Parkinson's disease].
Topics: Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Huma | 2000 |
Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease.
Topics: Aged; Benserazide; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levo | 2001 |
Delay of simple reaction time after levodopa intake.
Topics: Adult; Aged; Antiparkinson Agents; Behavior; Benserazide; Cognition; Dopamine Agents; Drug Combinati | 2001 |
Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Clinical Tri | 1975 |
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
Topics: Administration, Oral; Aged; Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Combi | 1977 |
Comparison of levodopa with carbidopa or benserazide in parkinsonism.
Topics: Aged; Benserazide; Carbidopa; Consumer Behavior; Drug Administration Schedule; Drug Evaluation; Drug | 1976 |
[Levodopa and decarboxylase inhibitors in Parkinson's disease].
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydrazines; Lev | 1977 |
Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Clinical Trials as Topic; Drug | 1978 |
A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
Topics: Adult; Benserazide; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Fem | 1978 |
Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
Topics: Activities of Daily Living; Aged; Benserazide; Clinical Trials as Topic; Drug Combinations; Female; | 1979 |
[The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodo | 1979 |
Levodopa with benserazide or carbidopa in Parkinson disease.
Topics: Benserazide; Biological Availability; Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Com | 1979 |
Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
Topics: Aged; Azides; Benserazide; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug | 1976 |
[Sinomet and Madopar, a comparative study on the treatment of Parkinson's disease].
Topics: Benserazide; Carbidopa; Clinical Trials as Topic; Drug Combinations; Drug Evaluation; Humans; Levodo | 1976 |
Madopar versus sinemet. A clinical study on their effectiveness.
Topics: Adult; Aged; Benserazide; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydr | 1975 |
Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Levodopa; Male; | 1975 |
Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodo | 1976 |
Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
Topics: Benserazide; Bromocriptine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lev | 1992 |
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients.
Topics: Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies; Humans; L | 1992 |
A single-dose study of the pharmacodynamic effects of chlormethiazole, temazepam and placebo in elderly parkinsonian patients.
Topics: Aged; Benserazide; Carbidopa; Chlormethiazole; Double-Blind Method; Drug Therapy, Combination; Femal | 1991 |
A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Response Relationship, D | 1991 |
Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Topics: Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Dopamine; | 1990 |
A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Dose-Respo | 1990 |
Levodopa treatment of Parkinson's syndrome: past and future.
Topics: Benserazide; Brain; Carboxy-Lyases; Drug Therapy, Combination; Forecasting; Humans; Levodopa; Parkin | 1990 |
Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Adminis | 1990 |
Madopar HBS in nocturnal symptoms of Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Circadian Rhythm; Delayed-Action Preparations; Dose-Respon | 1990 |
Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
Topics: Adult; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Femal | 1990 |
Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: two years of follow-up.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; | 1990 |
Tetrahydrobiopterin and Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Biopterins; Clinical Trials as Topic; Drug Combinations; H | 1989 |
A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
Topics: Activities of Daily Living; Aged; Benserazide; Circadian Rhythm; Delayed-Action Preparations; Double | 1989 |
A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Topics: Administration, Oral; Benserazide; Clinical Trials as Topic; Drug Administration Schedule; Drug Comb | 1988 |
A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; Dr | 1988 |
Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Dru | 1988 |
The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
Topics: Benserazide; Clinical Trials as Topic; Disability Evaluation; Drug Therapy, Combination; Female; Hum | 1987 |
Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind M | 1987 |
Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Female; | 1987 |
Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relat | 1987 |
Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Benserazide; Biological Availability; Clinical Trials as Topic; D | 1987 |
Open clinical study of Madopar HBS.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relat | 1987 |
Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relat | 1987 |
Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; | 1987 |
Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Topics: Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug | 1987 |
Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Topics: Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship | 1987 |
Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Topics: Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; | 1987 |
[Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Delayed-Action Preparations; Dru | 1987 |
Mesulergine in early Parkinson's disease: a double blind controlled trial.
Topics: Aged; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combina | 1986 |
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Clinical Trials as Topic; Delayed-Action Preparations; Disa | 1987 |
Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Topics: Activities of Daily Living; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbido | 1985 |
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dermatitis, Seborrheic; Dihydroxyphenylalanin | 1974 |
[Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Combinations; Ev | 1973 |
Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hydra | 1974 |
226 other studies available for benserazide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Identification by virtual screening and in vitro testing of human DOPA decarboxylase inhibitors.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Catalytic Domain; Chemistry, Pharmaceutical; | 2012 |
Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.
Topics: Animals; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Dose-Response Relatio | 2012 |
The relationship between the distinct ratios of benserazide and carbidopa to levodopa and motor complications in Parkinson's disease: A retrospective cohort study.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2022 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Ind | 2023 |
Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Homocysteine; Humans; Insulin-Like Growth Factor I; Levodop | 2023 |
Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
Topics: Aged; Antiparkinson Agents; Benserazide; Computer Simulation; Conditioning, Operant; Dopamine Agonis | 2020 |
Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Sickle Cell; Antiparkinson Agents; Antisickling Agents; Bens | 2021 |
Levodopa/dopa decarboxylase inhibitor associated microscopic colitis: An under-recognized drug reaction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Cohort Studies; Colitis, Micr | 2021 |
Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Benserazide; Case-Control Studies; Cross-Sectional Stud | 2017 |
Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis.
Topics: Adsorption; Benserazide; Electrons; Hydrogen Bonding; Levodopa; Models, Molecular; Molecular Conform | 2018 |
Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report.
Topics: Anisotropy; Antiparkinson Agents; Benserazide; Diffusion Tensor Imaging; Drug Combinations; Female; | 2017 |
The nature of postural tremor in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cluster Analysis; Dopamine; Drug | 2018 |
Cortical response to levodopa in Parkinson's disease patients with dyskinesias.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Brain; Drug Combinations; Dyskinesia, Dr | 2018 |
A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin.
Topics: Amyloid; Benserazide; Cell Line, Tumor; Cell Survival; Dopamine Agents; Drug Combinations; Humans; L | 2019 |
Sit-to-walk performance in Parkinson's disease: A comparison between faller and non-faller patients.
Topics: Accidental Falls; Aged; Aged, 80 and over; Benserazide; Case-Control Studies; Drug Combinations; Fem | 2019 |
Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.
Topics: Benserazide; Capsules; Color; Dopamine Agents; Drug Combinations; Drugs, Generic; Humans; Levodopa; | 2013 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dise | 2011 |
Zoophilia and Parkinson's disease.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Humans; Levodopa; Male; Middle Aged; Parkinson | 2013 |
Reduction in Parkinson's disease therapy improved punding but not feeling of presence.
Topics: Antiparkinson Agents; Benserazide; Compulsive Behavior; Emotions; Female; Humans; Levodopa; Middle A | 2013 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, | 2014 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dop | 2015 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Pr | 2014 |
Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats.
Topics: Animals; Antioxidants; Benserazide; Betaine; Brain; Dopamine; Dopamine Agents; Drug Combinations; Gl | 2015 |
Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Topics: Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Drug Administration Schedule; Dyskin | 2015 |
L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Topics: Animals; Antidiarrheals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Ac | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dop | 2015 |
Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Diagnosis, Differential; Dopamine Agents; Drug Combinat | 2016 |
Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Dopamine; Dopam | 2016 |
PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Topics: Animals; Benserazide; Biological Transport; Dopamine Plasma Membrane Transport Proteins; Levodopa; M | 2016 |
[Benefits of the combination of mucuna, green tea and levodopa/benserazide in Parkinson's disease].
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Humans; Levodopa; Mucuna; Parkinson Di | 2016 |
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperho | 2016 |
Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benserazide; Conditioning, Operant; Disease Models, Animal; Evoked Po | 2016 |
Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease.
Topics: Adipocytes; Adipose Tissue; Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Dru | 2008 |
Acute stepwise challenge test with levodopa in treated patients with parkinsonism.
Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Cohort Studies; Deep Brain Stimulation; Demog | 2009 |
Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Benzothiazoles; Brain; Carbidopa; Dopamine Agents; Dystonia; F | 2009 |
Severe gastroparesis in a patient with advanced Parkinson's disease.
Topics: Aged, 80 and over; Benserazide; Dopamine Agents; Drug Combinations; Enzyme Inhibitors; Follow-Up Stu | 2009 |
Complementary acupuncture treatment increases cerebral metabolism in patients with Parkinson's disease.
Topics: Acupuncture Therapy; Aged; Antiparkinson Agents; Benserazide; Brain Chemistry; Combined Modality The | 2009 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; | 2010 |
Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.
Topics: Antiparkinson Agents; Antithyroid Agents; Benserazide; Carbimazole; Drug Combinations; Female; Grave | 2010 |
Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Corpus Striatum; Dopamine; Dopamine Ag | 2010 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; | 2011 |
Analysis of differences between physiological and pathological tremor of human fingers.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Electromyography; Fingers; Humans; Isometric C | 2010 |
Parkinsonism complicating acute organophosphate insecticide poisoning.
Topics: Acute Disease; Adult; Antidotes; Antiparkinson Agents; Benserazide; Cholinesterase Inhibitors; Human | 2011 |
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance.
Topics: Aged; Benserazide; Benzothiazoles; Carbidopa; Cues; Deep Brain Stimulation; Dopamine Agents; Drug Co | 2011 |
The function of dopaminergic neural signal transmission in auditory pulse perception: evidence from dopaminergic treatment in Parkinson's patients.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Auditory Perception; Benserazide; Cohort Studies; | 2011 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 2011 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Pheno | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; An | 2013 |
[Hyperprolactinemia and gynaecomastia induced by benserazide].
Topics: Aged; Antiparkinson Agents; Benserazide; Gynecomastia; Humans; Hyperprolactinemia; Male; Parkinson D | 2012 |
Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
Topics: Ankle; Antiparkinson Agents; Benserazide; Benzothiazoles; Drug Therapy, Combination; Edema; Humans; | 2012 |
Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Benserazide; Canada; Caregivers; Cost Savings; Dopamine Agonists; Drug | 2003 |
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; | 2003 |
Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benserazide; Case-Control Studies; Dyskinesias; Female | 2003 |
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cabergoline; Ergolines; Humans; Levodopa | 2003 |
Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.
Topics: Antiparkinson Agents; Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Homeostasis; | 2006 |
Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Denervation; | 2006 |
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Brain; Disease Mo | 2006 |
Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Blood Pressure; Cerebrovascular Circulation; Drug Synergism | 2007 |
[Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
Topics: Benserazide; Dopamine; Endorphins; Humans; Hypothalamo-Hypophyseal System; Levodopa; Nerve Tissue Pr | 1984 |
[Combined (surgical and drug) therapy of parkinsonism].
Topics: Benserazide; Catecholamines; Combined Modality Therapy; Diencephalon; Drug Combinations; Humans; Hyd | 1984 |
DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
Topics: Aged; Antiparkinson Agents; Benserazide; Blood Pressure; Dizziness; Droxidopa; Drug Therapy, Combina | 1983 |
Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.
Topics: Aged; Benserazide; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
L-deprenyl in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug | 1983 |
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
Topics: Aged; Benserazide; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug | 1983 |
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; | 1983 |
Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
Topics: Aged; Benserazide; Droxidopa; Gait; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Parkinson Di | 1984 |
Combined use of benserazide and carbidopa in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; Levodopa; Male; | 1984 |
Dystonia--L-dopa responsive or juvenile parkinsonism?
Topics: Adolescent; Benserazide; Carbidopa; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug | 1983 |
[Exploration of the tubero-hypophyseal dopaminergic system in patients with chronic parkinsonism during chronic treatment with L-DOPA].
Topics: Aged; Benserazide; Blood-Brain Barrier; Humans; Hypothalamo-Hypophyseal System; Levodopa; Male; Park | 1983 |
Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
Topics: Benserazide; Bromocriptine; Dopamine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1983 |
Response to Sinemet 25/100 in Parkinson's disease.
Topics: Aged; Benserazide; Body Weight; Carbidopa; Drug Combinations; Drug Therapy, Combination; Female; Hum | 1984 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Age | 1980 |
Long-term responses of Parkinson's disease to levodopa therapy.
Topics: Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Levodopa; Long-Term Care; Male; Parkin | 1980 |
[Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Topics: Aged; Benserazide; Drug Combinations; Electromyography; Female; Homovanillic Acid; Humans; Hydrazine | 1980 |
Effect of levodopa on thyroid function and prolactin release. A study in patients with Parkinson's disease.
Topics: Aged; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkin | 1981 |
The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels.
Topics: 5-Hydroxytryptophan; Adult; Benserazide; Carbidopa; Chlorpromazine; Dihydroxyphenylalanine; Humans; | 1982 |
Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide.
Topics: Benserazide; Drug Administration Schedule; Female; Humans; Hydrazines; Levodopa; Middle Aged; Parkin | 1982 |
Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydraz | 1982 |
Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Topics: Aged; Animals; Benserazide; Carbidopa; Dose-Response Relationship, Drug; Drug Combinations; Drug The | 1982 |
Parkinsonism in the elderly.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Humans; Levodopa; Parkinson Disease | 1982 |
New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
Topics: Adult; Aged; Benserazide; Carbidopa; Choline; Cytidine Diphosphate Choline; Dose-Response Relationsh | 1982 |
L-dopa competes with tyrosine and tryptophan for human brain uptake.
Topics: Aged; Benserazide; Blood-Brain Barrier; Brain; Female; Humans; Levodopa; Male; Parkinson Disease; Tr | 1980 |
Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Drug Combinations; Female; Growth Hormone; Humans; H | 1981 |
[Madopar in the treatment of paralysis agitans. I. Therapeutic efficacy and side-effects in 56 cases (author's transl)].
Topics: Adult; Benserazide; Electrocardiography; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; M | 1980 |
Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Benzyl Compounds; Carbidopa; Catechol O-Methyl | 1980 |
Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and semicarbazide-sensitive amine oxidase in Parkinson's disease.
Topics: Aged; Amine Oxidase (Copper-Containing); Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; | 1995 |
[Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Combinat | 1995 |
Parkinsonian medication one hour before meals improves symptomatic swallowing: a case study.
Topics: Administration, Oral; Aged; Benserazide; Bromocriptine; Deglutition; Deglutition Disorders; Drug Adm | 1995 |
[Tumoral Parkinson hemi-syndrome sensitive to L-dopa].
Topics: Benserazide; Brain Neoplasms; Drug Therapy, Combination; Glioblastoma; Humans; Levodopa; Magnetic Re | 1994 |
[Bromocriptine-induced pleuropneumopathy].
Topics: Benserazide; Biperiden; Bromocriptine; Humans; Levodopa; Lung Diseases; Male; Middle Aged; Parkinson | 1994 |
[Akinetic crisis in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Benserazide; Drug Therapy, Combination; Female; Humans; Levodo | 1994 |
Cografts of adrenal medulla with peripheral nerve for Parkinson's disease.
Topics: Adrenal Medulla; Adrenalectomy; Adult; Benserazide; Drug Therapy, Combination; Female; Follow-Up Stu | 1994 |
Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease.
Topics: Aged; Benserazide; Blood Cell Count; Clozapine; Female; Hallucinations; Humans; Levodopa; Male; Midd | 1993 |
Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease.
Topics: Aged; Benserazide; Biogenic Monoamines; China; Chromatography, High Pressure Liquid; Female; Humans; | 1993 |
Parkinson's disease study.
Topics: Benserazide; Bias; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease | 1993 |
Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Topics: Adult; Basal Ganglia; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Huma | 1993 |
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
Topics: Benserazide; Carbidopa; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Motor | 1993 |
Nocturnal akathisia in Parkinson's disease: treatment with clozapine.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Carbidopa; Circadian Rhythm; Clozapine; Confusion; Dose | 1993 |
Treatment of Parkinson's disease in a patient with acute intermittent porphyria.
Topics: Aged; Antiparkinson Agents; Benserazide; Chlorpromazine; Dopamine Antagonists; Drug Interactions; Fe | 1995 |
[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Dose-Response Relations | 1995 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxi | 1996 |
Swallowing difficulty in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Barium Sulfate; Benserazide; Contrast Media; D | 1997 |
[L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
Topics: Adult; Animals; Antiparkinson Agents; Benserazide; Carbonic Anhydrase Inhibitors; Drug Therapy, Comb | 1997 |
Clinical implications of sustained dopaminergic stimulation.
Topics: Aged; Benserazide; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Dys | 1994 |
[Madopar: more than 20 years].
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; History, 20th Century; Humans | 1997 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors | 1998 |
Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benserazide; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1998 |
L-dopa pharmacokinetics studied with microdialysis in patients with Parkinson's disease and a history of malignant melanoma.
Topics: Aged; Antiparkinson Agents; Benserazide; Female; Humans; Levodopa; Male; Melanoma; Microdialysis; Mi | 1999 |
The reach-to-grasp movement in Parkinson's disease before and after dopaminergic medication.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia; Benserazide; Carbidopa; Drug Combinations; Female; | 2000 |
The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Cells, Cultu | 2000 |
[A case of delusional jealousy in Parkinson disease ].
Topics: Antiparkinson Agents; Benserazide; Delusions; Dose-Response Relationship, Drug; Drug Combinations; H | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chro | 2001 |
Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Bensera | 2001 |
Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Be | 2001 |
[Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbid | 2002 |
[Therapy of Parkinson's disease. Practical criteria of treatment].
Topics: Amantadine; Antiparkinson Agents; Benserazide; Carbidopa; Cyproheptadine; Drug Therapy, Combination; | 1976 |
Uptake and efflux of 14-C-dopamine in platelets: evidence for a generalized defect in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Platelets; | 1975 |
Dose-related levodopa-induced haemolytic anaemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Autoantibodies; Benserazide; Dose-Response Relationship, Drug; | 1977 |
Pharmaceutical review: salbutamol - madopar - isocal.
Topics: Albuterol; Australia; Benserazide; Humans; Hydrazines; Levodopa; Lung Diseases; Parenteral Nutrition | 1978 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, HCL-benserazide, on Parkinson's disease-part I: clinical aspects (author's transl)].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Blood Pressure; Dopa Decarbo | 1979 |
[Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Female; | 1979 |
Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
Topics: Adolescent; Adult; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Hydrazines; Levodopa; Male | 1979 |
["Immune type" haemolysis in course of L. dopa-benserazide therapeutic (author's transl)].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benserazide; Coombs Test; Female; Humans; Hydrazines; Levodopa; | 1979 |
Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dihydroxyphenylalanine; Female | 1978 |
Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
Topics: Aged; Benserazide; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydraz | 1977 |
Treating parkinsonism with L-dopa and carboxylase inhibitor.
Topics: Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; P | 1977 |
Plasma O-methyldopa in levodopa-induced dyskinesias. A bioclinical investigation.
Topics: Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methyldopa; | 1977 |
Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Topics: Benserazide; Brain; Bromocriptine; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; P | 1978 |
Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Therapy, Com | 1978 |
Long term treatment with L-deprenyl.
Topics: Benserazide; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Phenethylamines; Selegi | 1978 |
L-deprenyl treatment of on-off phenomena in Parkinson's disease.
Topics: Aged; Benserazide; Dopamine; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydroxyin | 1978 |
[Therapy of Parkinson's syndrome].
Topics: Amantadine; Benserazide; Carbidopa; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Physica | 1976 |
[Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
Topics: Adult; Benserazide; Drug Combinations; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Long-T | 1976 |
Serum dopamine-beta-hydroxylase in parkinsonism.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dopamine beta-Hydroxylase; Humans; | 1977 |
Effect of L-dopa on polycythemia.
Topics: Aged; Benserazide; Drug Evaluation; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkins | 1977 |
Levodopa in parkinsonism.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Li | 1977 |
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
Topics: Benserazide; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydrazines; Hydroxyindole | 1977 |
Does O-methyl-dopa play a role in levodopa-induced dyskinesias?
Topics: Adult; Aged; Benserazide; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Methy | 1977 |
["Beginning and end of dose" dyskinesias caused by L-DOPA].
Topics: Benserazide; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Hydrazines; Levodo | 1977 |
Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Mid | 1976 |
Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
Topics: Adult; Aged; Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Mid | 1976 |
In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopamine; Drug Intera | 1976 |
Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
Topics: Benserazide; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; Male; Middle Aged; Par | 1976 |
Prolonged symptoms of brain dysfunction--adverse effect of levodopa.
Topics: Aged; Benserazide; Brain Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Parkinson Di | 1976 |
[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Topics: Adult; Aged; Benserazide; Carbidopa; Dihydroxyphenylalanine; Dopamine; Drug Therapy, Combination; Fe | 1976 |
[5 years of experience in the treatment of parkinsonism with L-dopa and its combination with Ro4-4602].
Topics: Adult; Aged; Benserazide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Le | 1976 |
Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Drug Evaluation; Humans; Levod | 1975 |
Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; | 1975 |
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; H | 1975 |
[Long-term syndrome in the treatment of parkinsonism with L-dopa].
Topics: Benserazide; Drug Evaluation; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Time F | 1975 |
Idiopathic hemiparetic parkinsonism, a syndrome distinct from idiopathic parkinsonism.
Topics: Adult; Benserazide; Drug Combinations; Female; Hemiplegia; Humans; Levodopa; Parkinson Disease; Post | 1992 |
The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease.
Topics: Benserazide; Carbidopa; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease | 1992 |
Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features.
Topics: Adult; Age Factors; Benserazide; Biomarkers; Biopterins; Carbidopa; Female; Humans; Levodopa; Male; | 1992 |
Paradoxical akinetic response to apomorphine in parkinsonism.
Topics: Apomorphine; Benserazide; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Hu | 1992 |
Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Topics: Adult; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Age | 1992 |
Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
Topics: Aged; Amyloidosis; Benserazide; Blood Platelets; Dose-Response Relationship, Drug; Droxidopa; Drug T | 1991 |
Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Cognition Disorders; Female; Homovanillic Acid; | 1990 |
[Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
Topics: Aged; Benserazide; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced | 1991 |
Central action of benserazide after COMT inhibition demonstrated in vivo by PET.
Topics: Animals; Benserazide; Benzophenones; Brain; Catechol O-Methyltransferase Inhibitors; Levodopa; Macac | 1991 |
(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity.
Topics: Aged; Benserazide; Catechol O-Methyltransferase; Erythrocytes; Female; Humans; Kinetics; Levodopa; M | 1991 |
Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction.
Topics: Adult; Autonomic Nervous System Diseases; Benserazide; Delayed-Action Preparations; Drug Combination | 1991 |
The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
Topics: Administration, Oral; Aged; Benserazide; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson | 1991 |
Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Benserazide; Carboxy-Lyases; Delayed-Action Preparations; Drug Combinations; Follow-Up Studies | 1990 |
Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
Topics: Aged; Benserazide; Bromocriptine; Drug Therapy, Combination; Humans; Levodopa; Male; Middle Aged; Pa | 1990 |
Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Carboxy-Lyases; Dose-Response Relationship, Drug | 1990 |
The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
Topics: Benserazide; Depression; Double-Blind Method; Drug Therapy, Combination; Female; Glycols; Homovanill | 1989 |
Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Le | 1989 |
Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Delayed-Action Preparations; Drug Combinations; | 1989 |
Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar.
Topics: Aged; Aged, 80 and over; Benserazide; Drug Combinations; Female; Humans; Hydrazines; Isoquinolines; | 1989 |
Disability profiles and objective quantitative assessment in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Drug Combinations; Female; Humans; Levod | 1989 |
[Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
Topics: Antiparkinson Agents; Benserazide; Drug Administration Schedule; Drug Combinations; Humans; Levodopa | 1989 |
[The problems of L-dopa therapy in the course of Parkinson syndrome].
Topics: Adult; Aged; Benserazide; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug T | 1989 |
Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Topics: Aged; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Carboxy-Lyases; Drug Combinations; Drug The | 1989 |
Pregnancy and parkinsonism. A case report without problem.
Topics: Adult; Benserazide; Drug Combinations; Female; Humans; Infant, Newborn; Levodopa; Parkinson Disease; | 1989 |
Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
Topics: Administration, Oral; Aged; Benserazide; Carboxy-Lyases; Catecholamines; Dopa Decarboxylase; Drug Co | 1989 |
[The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Topics: Adult; Aged; Benserazide; Carboxy-Lyases; Drug Combinations; Enkephalin, Leucine; Female; Homovanill | 1989 |
Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.
Topics: Aged; Antipsychotic Agents; Benserazide; Bromocriptine; Clozapine; Delusions; Dibenzazepines; Dose-R | 1985 |
Painful Parkinson's disease.
Topics: Acute Disease; Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Administration Schedu | 1986 |
Optimization of symptomatic therapy in Parkinson's disease.
Topics: Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Computer-Assisted; H | 1989 |
[An open study of a new formulation of the levodopa and benserazide combination in the treatment of fluctuations of motor performance in patients with Parkinson's disease].
Topics: Aged; Benserazide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydrazines; Levodopa; | 1988 |
Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy.
Topics: Adult; Aged; Benserazide; Dopamine; Drug Combinations; Female; Growth Hormone; Humans; Hypothalamo-H | 1986 |
MPTP: clinical implications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Basal Ganglia; Benserazide; Drug Combinations; D | 1986 |
Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Topics: Aged; Aged, 80 and over; Benserazide; Bromocriptine; Confusion; Drug Combinations; Dyskinesia, Drug- | 1986 |
Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Topics: Benserazide; Drug Combinations; Drug Therapy, Combination; Humans; Hydrazines; Levodopa; Parkinson D | 1986 |
(-)Deprenyl in the treatment of decompensated Parkinson's disease.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Movement Disorders; Parkinson Disease; | 1986 |
[Therapeutic strategies and tactics in parkinsonism].
Topics: Amantadine; Antidepressive Agents; Antiparkinson Agents; Benserazide; Carbidopa; Depressive Disorder | 1986 |
Current and future approaches to therapy.
Topics: Antiparkinson Agents; Benserazide; Bromocriptine; Carbidopa; Drug Therapy, Combination; Humans; Levo | 1987 |
Madopar HBS in Parkinson patients with nocturnal akinesia.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines | 1988 |
Outpatient treatment of Parkinson's disease.
Topics: Ambulatory Care; Benserazide; Bromocriptine; Carboxy-Lyases; Drug Combinations; Dyskinesia, Drug-Ind | 1988 |
Madopar HBS. International workshop on the 'on-off-phenomenon in Parkinson's disease. New possibilities for its management. Agno, November 14-16, 1985.
Topics: Benserazide; Drug Combinations; Humans; Hydrazines; Levodopa; Parkinson Disease | 1987 |
Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
Topics: Aged; Benserazide; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; | 1987 |
A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease.
Topics: Benserazide; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydra | 1987 |
Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Topics: Aged; Aged, 80 and over; Benserazide; Biological Availability; Delayed-Action Preparations; Dose-Res | 1987 |
Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Topics: Adult; Aged; Benserazide; Delayed-Action Preparations; Drug Combinations; Female; Humans; Hydrazines | 1987 |
Therapeutic value of Madopar HBS: judgment after 2 years experience.
Topics: Adult; Aged; Aged, 80 and over; Benserazide; Delayed-Action Preparations; Dose-Response Relationship | 1987 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders.
Topics: 5-Hydroxytryptophan; Adult; Aged; Benserazide; Cerebellar Ataxia; Drug Therapy, Combination; Female; | 1987 |
Management of Parkinson's disease in general practice.
Topics: Aged; Benserazide; Bromocriptine; Carbidopa; Drug Combinations; Family Practice; Humans; Levodopa; M | 1986 |
Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Domperidone; Drug Therapy, Combination; Female; Humans; Levodop | 1986 |
Individual levodopa therapy in Parkinson's disease.
Topics: Benserazide; Chromatography, High Pressure Liquid; Drug Combinations; Gait; Humans; Levodopa; Parkin | 1987 |
[L-dopa therapy of parkinson syndrome].
Topics: Benserazide; Biotransformation; Carbidopa; Corpus Striatum; Dopamine; Dose-Response Relationship, Dr | 1985 |
Deprenyl in Parkinson disease: personal experience.
Topics: Adult; Aged; Benserazide; Carbidopa; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Midd | 1985 |
Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Autonomic Nervous System; Benserazide; Blood Pre | 1985 |
Inhibitory effect of drugs used in the treatment of Parkinson's disease on plasma monoamine oxidase activity.
Topics: Adult; Aged; Benserazide; Benzylamine Oxidase; Carbidopa; Female; Humans; Hydrazines; Isoenzymes; Ma | 1985 |
[The L-dopa test in Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Drug Therapy, Combination; Female; | 1985 |
[Drug therapy of Parkinson's disease].
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Levodo | 1985 |
[Clinical significance of cramps of the lower extremities in patients with parkinsonism].
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Drug Combinations; Female; Humans; Hydrazines; L | 1985 |
[A case of L-dopa induced autoimmune hemolytic anemida].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benserazide; Humans; Levodopa; Male; Parkinson Disease | 1985 |
[Dopamine and abnormal movements].
Topics: Benserazide; Body Weight; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Electro | 1972 |
[Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzyl Compounds; Carbidopa; Drug Therapy | 1974 |
[Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
Topics: Adult; Aged; Benserazide; Capsules; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Combinations; Drug | 1974 |
[Modification of disturbed visual-spatial performance in patients with Parkinson's disease by treatment with L-dopa].
Topics: Aged; Benserazide; Drug Therapy, Combination; Female; Form Perception; Humans; Intelligence Tests; L | 1974 |
[The association of L-DOPA and Ro 4-4602 in the treatment of Parkinson's disease (author's transl)].
Topics: Benserazide; Drug Combinations; Drug Evaluation; Humans; Hydrazines; Levodopa; Parkinson Disease | 1974 |
[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
Topics: Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Drug Therapy, Combination; Hu | 1974 |
[Indications and results of monoamine treatment in parkinsonian syndromes].
Topics: Aged; Arrhythmias, Cardiac; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Combinations; | 1972 |
[Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Topics: Aged; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Evaluation; Electromyography; Humans | 1974 |
[Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
Topics: Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Combinations; Humans; Hydrazines; Parkinso | 1972 |
[Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
Topics: Aged; Benserazide; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; Drug Evaluation; Drug Therapy | 1973 |
Plasma concentration of levodopa in patients with Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Benserazide; Dihydroxyphenylalanine; Drug Combinations; Female; H | 1973 |
[Dopaminergic control of the diencephalo-pituitary axis for somatotropin secretion].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Diencephalon; Dihydroxypheny | 1973 |
Bensarazid with L-dopa in the treatment of parkinson's disease.
Topics: Adult; Aged; Benserazide; Dihydroxyphenylalanine; Drug Therapy, Combination; Female; Humans; Hydrazi | 1974 |
Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.
Topics: Adolescent; Adult; Aged; Benserazide; Biopsy; Caudate Nucleus; Child, Preschool; Corpus Striatum; Di | 1974 |
Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat.
Topics: Aged; Animals; Autoradiography; Benserazide; Brain; Carbon Radioisotopes; Carboxy-Lyases; Dihydroxyp | 1974 |
[L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dihydroxyphenylalanine; Drug | 1974 |